<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Aging Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Aging Neurosci</journal-id><journal-id journal-id-type="publisher-id">Front. Aging Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Aging Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1663-4365</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40012862</article-id><article-id pub-id-type="pmc">PMC11861300</article-id><article-id pub-id-type="doi">10.3389/fnagi.2024.1454735</article-id><article-categories><subj-group subj-group-type="heading"><subject>Aging Neuroscience</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Study insights in the role of PGC-1&#x003b1; in neurological diseases: mechanisms and therapeutic potential</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Tang</surname><given-names>Mi-bo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2775327/overview"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yi-xuan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Zheng-wei</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/821632/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Hai-yang</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/757429/overview"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Shuo</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/871183/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Chang-he</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/424834/overview"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Yu-ming</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/424655/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Geriatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>NHC Key Laboratory of Prevention and Treatment of Cerebrovascular Diseases</institution>, <addr-line>Zhengzhou, Henan</addr-line>, <country>China</country></aff><aff id="aff4"><sup>4</sup><institution>Henan Key Laboratory of Cerebrovascular Diseases, Zhengzhou University</institution>, <addr-line>Zhengzhou, Henan</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by" id="fn0001"><p>Edited by: Zhiquan Li, University of Copenhagen, Denmark</p></fn><fn fn-type="edited-by" id="fn0002"><p>Reviewed by: Jiangbo Song, Southwest University, China</p><p>Claudia Navarro, University of Copenhagen, Denmark</p></fn><corresp id="c001">*Correspondence: Mi-bo Tang, <email>tangmibohappy@126.com</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>16</volume><elocation-id>1454735</elocation-id><history><date date-type="received"><day>25</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Tang, Liu, Hu, Luo, Zhang, Shi and Xu.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Tang, Liu, Hu, Luo, Zhang, Shi and Xu</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> coactivator-1&#x003b1; (PGC-1&#x003b1;), which is highly expressed in the central nervous system, is known to be involved in the regulation of mitochondrial biosynthesis, metabolic regulation, neuroinflammation, autophagy, and oxidative stress. This knowledge indicates a potential role of PGC-1&#x003b1; in a wide range of functions associated with neurological diseases. There is emerging evidence indicating a protective role of PGC-1&#x003b1; in the pathogenesis of several neurological diseases. As such, a deeper and broader understanding of PGC-1&#x003b1; and its role in neurological diseases is urgently needed. The present review provides a relatively complete overview of the current knowledge on PGC-1&#x003b1;, including its functions in different types of neurons, basic structural characteristics, and its interacting transcription factors. Furthermore, we present the role of PGC-1&#x003b1; in the pathogenesis of various neurological diseases, such as intracerebral hemorrhage, ischemic stroke, Alzheimer&#x02019;s disease, Parkinson&#x02019;s disease, Amyotrophic lateral sclerosis, Huntington&#x02019;s disease, and other PolyQ diseases. Importantly, we discuss some compounds or drug-targeting strategies that have been studied to ameliorate the pathology of these neurological diseases and introduce the possible mechanistic pathways. Based on the available studies, we propose that targeting PGC-1&#x003b1; could serve as a promising novel therapeutic strategy for one or more neurological diseases.</p></abstract><kwd-group><kwd>PGC-1&#x003b1;</kwd><kwd>mitochondria</kwd><kwd>neuroinflammation</kwd><kwd>oxidative stress</kwd><kwd>neurological diseases</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This review was supported by the National Natural Science Foundation of China (Grant 82101491 to Mi-bo Tang) and the Henan Province Science and Technology Innovation Talent Program (Grant LHGJ 20210296 to Mi-bo Tang).</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="4"/><equation-count count="0"/><ref-count count="157"/><page-count count="12"/><word-count count="11162"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Cellular and Molecular Mechanisms of Brain-aging</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><label>1</label><title>Introduction</title><p>Mitochondria are vital organelles of eukaryotic cells that contain their own DNA.</p><p>In addition to ATP production, mitochondria play a crucial role in signaling and regulation across various pathways. Among these, calcium signaling stands out as a key mechanism through which mitochondria can regulate several cellular processes (<xref rid="ref95" ref-type="bibr">Nunnari and Suomalainen, 2012</xref>). Mitochondrial biogenesis depends on the coordination between nuclear and mitochondrial DNA. The PPAR&#x003b3; coactivator-1 family (PGC-1) of transcription coactivators, including sirtuins and AMPK, is involved in regulating gene expression during mitochondrial biogenesis, as are mitochondrial transcription factor A (TFAM) and nuclear respiratory factors 1 and 2 (NRF1 and NRF2).</p><p>Neurons are high energy-demanding cells that require a tight regulation of Ca<sup>2+</sup> to maintain their action potentials. Mitochondrial disorders have been reported in many neurological diseases. However, the exact mechanisms underlying the mitochondrial dysfunction vary between diseases. PGC-1&#x003b1; is conserved in eukaryotes and is particularly highly expressed in high-energy-consuming tissues and organs, such as brown adipose tissue, skeletal muscle, heart, liver, and brain. As a significant upstream molecule and downstream target of many vital pathways, PGC-1&#x003b1; is involved in the sophisticated crosstalk between neurons. In addition to acting as a master regulator of mitochondrial biogenesis (<xref rid="ref60" ref-type="bibr">Jornayvaz and Shulman, 2010</xref>; <xref rid="ref32" ref-type="bibr">Fan et al., 2024</xref>), PGC-1&#x003b1; also combats oxidative stress in neurons (<xref rid="ref63" ref-type="bibr">Kong et al., 2010</xref>; <xref rid="ref127" ref-type="bibr">Wang D. et al., 2022</xref>), protects against neuroinflammation (<xref rid="ref7" ref-type="bibr">Ayasolla et al., 2005</xref>; <xref rid="ref110" ref-type="bibr">Sun et al., 2024</xref>), functions as an upstream activator of neuro-autophagy (<xref rid="ref118" ref-type="bibr">Tsunemi et al., 2012</xref>), and suppresses neuro-apoptosis (<xref rid="ref140" ref-type="bibr">Wu et al., 2018</xref>). This review summarizes the current knowledge regarding the functions of PGC-1&#x003b1; in the brain and its role in neurological diseases, such as intracerebral hemorrhage (ICH), ischemic stroke, Alzheimer&#x02019;s disease (AD), Parkinson&#x02019;s disease (PD), Amyotrophic lateral sclerosis (ALS), and Polyglutamine (PolyQ) diseases. We hope that this review will facilitate future exploration of neurological diseases and promote the possible use of PGC-1&#x003b1; agonists/inhibitors as a new therapeutic strategy.</p></sec><sec id="sec2"><label>2</label><title>Role of PGC-1&#x003b1; in the central nervous system</title><p>PGC-1&#x003b1; is abundant in the brain, particularly in the cerebral cortex, striatum, globus pallidus, and substantia nigra (SN), whereas it is absent in the hypothalamus (<xref rid="ref117" ref-type="bibr">Tritos et al., 2003</xref>). The abnormal distribution of PGC-1&#x003b1; in the central nervous system, to some extent, explains its diverse roles in the physiological functions of different cell types (<xref rid="fig1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="fig1"><label>Figure 1</label><caption><p>Role of PGC-1&#x003b1; in the central nervous system. The key role of PGC-1&#x003b1; in the maturation, differentiation, functioning, and survival of different neuron types across the central nervous system.</p></caption><graphic xlink:href="fnagi-16-1454735-g001" position="float"/></fig><sec id="sec3"><label>2.1</label><title>Excitatory neurons of the cerebral cortex</title><p>PGC-1&#x003b1; expression is enriched in GABAergic interneurons expressing parvalbumin and glutamatergic projection neurons, particularly those located in the cortical pyramidal layer V, which contains both inhibitory and excitatory neurons (<xref rid="ref23" ref-type="bibr">Cowell et al., 2007</xref>; <xref rid="ref81" ref-type="bibr">Lucas et al., 2010</xref>). Both glutamatergic and fast-spiking interneuron populations depend on PGC-1&#x003b1;. In neocortical and hippocampal excitatory neurons, PGC-1&#x003b1; was shown to impair calcium homeostasis, increase ROS levels, and maintain cells in a relatively inhibited state to balance the inhibition and excitation, as the deletion of PGC-1&#x003b1; from neocortical and hippocampal excitatory neurons caused enhanced glutamatergic transmission in the neocortex and hippocampus (<xref rid="ref87" ref-type="bibr">McMeekin et al., 2020</xref>). Motor neurons abundantly express PGC-1&#x003b1;. And increasing in PGC-1&#x003b1; mRNA are accompanied by voltage-gated currents characteristic of excitable cells and action potential formation when differentiating human embryonic stem cells or human neural stem cells into motor neurons (<xref rid="ref96" ref-type="bibr">O'Brien et al., 2015</xref>). Moreover, the survival of motor neurons was also found to increase after treatment with lactate to induce CNS-specific PGC-1&#x003b1; (<xref rid="ref10" ref-type="bibr">Bayer et al., 2017</xref>). Furthermore, the function of PGC-1&#x003b1; in motor neurons was also verified in studies of ALS (<xref rid="ref10" ref-type="bibr">Bayer et al., 2017</xref>; <xref rid="ref89" ref-type="bibr">Mehta et al., 2021</xref>). Together, these results indicate that PGC-1&#x003b1; is vital for the differentiation and function of motor neurons in the cerebral cortex.</p></sec><sec id="sec4"><label>2.2</label><title>Inhibitory neurons of the cerebral cortex and cerebellum</title><p>PGC-1&#x003b1; has heterogeneous functions in different nerve cells. Interneurons function to connect different types of CNS neurons, forming key nodes within brain neural circuitry. PGC-1&#x003b1; localizes in the nuclei of GABAergic interneurons, which form inhibitory synapses (<xref rid="ref23" ref-type="bibr">Cowell et al., 2007</xref>). One study revealed that PGC-1&#x003b1; regulated inhibitory signaling via the control of the Ca<sup>2+</sup>&#x02013;binding protein parvalbumin (<xref rid="ref81" ref-type="bibr">Lucas et al., 2010</xref>), and the balance between inhibition and excitation of synapses in the hippocampus was also suggested to depend on sufficient levels of PGC-1&#x003b1; (<xref rid="ref9" ref-type="bibr">Bartley et al., 2015</xref>; <xref rid="ref132" ref-type="bibr">Wang et al., 2020</xref>). Moreover, PGC-1&#x003b1; upregulated the GABAR&#x003b1;2 subunit in the hippocampus and frontal cortex, causing anxiety-like changes in the behavior of the mice (<xref rid="ref123" ref-type="bibr">Vanaveski et al., 2021</xref>). Inhibitory signaling related to PGC-1<italic>&#x003b1;</italic> was also detected in Purkinje cells, the projection neurons in the cerebellum (<xref rid="ref103" ref-type="bibr">Rosin et al., 2015</xref>). All these results demonstrate the essential function of PGC-1&#x003b1; in inhibitory signaling in the brain.</p></sec><sec id="sec5"><label>2.3</label><title>Midbrain dopaminergic neurons</title><p>Dopaminergic neurons are localized in the midbrain. PGC-1&#x003b1; is essential for the proper functioning of dopaminergic neurons, and is involved in the regulation of their viability. Researchers found that PGC-1&#x003b1;-knockout adult mice lost dopaminergic neurons in the substantia nigra (<xref rid="ref56" ref-type="bibr">Jiang et al., 2016</xref>). Further, in the presence of overexpressed &#x003b1;-synuclein, dopaminergic neurons lacking PGC-1&#x003b1; were more predisposed to degradation (<xref rid="ref20" ref-type="bibr">Ciron et al., 2015</xref>). A few studies further showed that growth factors interact with PGC-1&#x003b1; to regulate its function via mitochondrial biogenesis, oxidative stress, and neuroinflammation (<xref rid="ref85" ref-type="bibr">Makela et al., 2014</xref>; <xref rid="ref106" ref-type="bibr">Selvakumar et al., 2018</xref>; <xref rid="ref33" ref-type="bibr">Fang et al., 2020</xref>). Several studies reported that PGC-1&#x003b1; was disadvantageous to dopaminergic neurons, as it might lead to developmental failures and the degeneration of dopaminergic neurons (<xref rid="ref19" ref-type="bibr">Ciron et al., 2012</xref>; <xref rid="ref21" ref-type="bibr">Clark et al., 2012</xref>). Together, the above information suggests that the levels of PGC-1&#x003b1; play a decisive role in whether it exerts protective or destructive effects.</p></sec><sec id="sec6"><label>2.4</label><title>Synaptogenesis</title><p>Synapses are vital for ensuring the nutritional requirements of neurons, particularly in mitochondrial transport. PGC-1&#x003b1; is also engaged in the process of synaptogenesis, with research showing that PGC-1&#x003b1; is involved in the development of dendritic spines and the formation of synaptic connections in the brain (<xref rid="ref18" ref-type="bibr">Cheng et al., 2012</xref>). PGC-1&#x003b1; also influences the postnatal functioning of synapses, preserving hippocampal synapses, and promoting the postnatal generation of excitatory synapses of astrocytes (<xref rid="ref18" ref-type="bibr">Cheng et al., 2012</xref>; <xref rid="ref148" ref-type="bibr">Zehnder et al., 2021</xref>). Furthermore, PGC-1&#x003b1; regulates neurotransmitter release via control of the expression of the calcium sensors synaptotagmin 2 and complexin 1 (<xref rid="ref80" ref-type="bibr">Lucas et al., 2014</xref>). Thus, PGC-1&#x003b1; is considered essential for the generation and functioning of synapses.</p></sec><sec id="sec7"><label>2.5</label><title>Spinal cord</title><p>Decrease in the level of PGC-1&#x003b1; was detected in regions affected by spinal cord injuries (SCI) compared to healthy tissue, suggesting that PGC-1&#x003b1; may be involved in the physiological functioning of the spinal cord (<xref rid="ref46" ref-type="bibr">Hu et al., 2015</xref>). PGC-1&#x003b1; overexpression was found to decrease apoptosis in spinal cord neurons after SCI (<xref rid="ref47" ref-type="bibr">Hu et al., 2016</xref>; <xref rid="ref79" ref-type="bibr">Liu et al., 2017</xref>). Further studies in ALS mice showed that body-wide overexpression of PGC-1&#x003b1; decreased the degeneration of neuromuscular junctions (<xref rid="ref74" ref-type="bibr">Liang et al., 2011</xref>). Activating PGC-1&#x003b1; ameliorated ischemic brain injury via PPAR&#x003b1;-GOT1 axis by reducing the pyroptosis of endothelial cells, which was also reported (<xref rid="ref128" ref-type="bibr">Wang et al., 2021</xref>). Microglial PGC-1&#x003b1; was found to be a promising therapeutic target for acute ischemic stroke by promoting autophagy and mitophagy through ULK1 and reducing NLRP3 activation (<xref rid="ref43" ref-type="bibr">Han et al., 2021</xref>). Overall, these results suggest that PGC-1&#x003b1; may protect against spinal cord neuron failure, which is associated with the pathogenesis of many diseases, including ALS and stroke.</p></sec><sec id="sec8"><label>2.6</label><title>Glial cells of central nervous system</title><p>The most well-known function of glia in adults is controlling the formation of myelin sheaths around axons, which allows for the rapid conduction of signals essential for nervous system function (<xref rid="ref54" ref-type="bibr">Jessen, 2004</xref>; <xref rid="ref82" ref-type="bibr">Ludwig and Das, 2022</xref>). Glia also maintains appropriate concentrations of ions and neurotransmitters in the neuronal environment. There is an increasing body of evidence to indicate that glial cells also function as essential regulators of the formation, maintenance, and function of synapses, which are the key functional units of the nervous system (<xref rid="ref49" ref-type="bibr">Hughes, 2021</xref>). The primary glial cell types in the CNS are astrocytes and oligodendrocytes. Astrocytes in the CNS regulate synapse formation and maintain the efficacy of synapses. PGC-1&#x003b1; was suggested to be important for the maturation of astrocytes (<xref rid="ref148" ref-type="bibr">Zehnder et al., 2021</xref>). In neuronal models constructed from differentiated iPSCs, the activation of mitochondrial biogenesis was linked to upregulation of PGC-1&#x003b1; and the neuronal to glial fate decision switch (<xref rid="ref6" ref-type="bibr">Augustyniak et al., 2019</xref>). Research further showed that deletion of PGC-1&#x003b1; resulted in the extended proliferation and hindered astrocyte morphogenesis (<xref rid="ref148" ref-type="bibr">Zehnder et al., 2021</xref>). The central function of oligodendrocytes is to generate myelin, which is an extended membrane from the cell that wraps tightly around axons. Indeed, research reported that there is a considerable increase in PGC-1&#x003b1; during myelination in rat brain (<xref rid="ref23" ref-type="bibr">Cowell et al., 2007</xref>). PGC-1&#x003b1; also plays several roles in myelination by regulating MBP expression and cholesterol metabolism in oligodendrocytes (<xref rid="ref141" ref-type="bibr">Xiang et al., 2011</xref>). Activation of PGC-1&#x003b1; by exercise has been shown to be linked to the enhancement of myelin thickness (<xref rid="ref52" ref-type="bibr">Jensen et al., 2018</xref>). In one <italic>in vitro</italic> study, PGC-1&#x003b1; was shown to be involved in the protection of oligodendrocyte progenitor cells (OPCs) under inflammatory conditions.</p></sec></sec><sec id="sec9"><label>3</label><title>Structure of PGC-1&#x003b1;</title><p>As a transcriptional coactivator, PGC-1&#x003b1; contains several domains with various functions. PGC-1 coactivators exert their transcriptional regulatory function by binding to a variety of transcription factors and nuclear receptors that recognize specific sequences on target genes (<xref rid="ref125" ref-type="bibr">Villena, 2015</xref>). The amino-terminal region of PGC-1&#x003b1; contains a highly conserved activation domain that serves as a surface for the recruitment of histone acetyltransferase proteins. This domain also contains several leucine-rich LXXL motifs, also termed NR boxes, which drive a coactivator signature essential for interactions with multiple types of other transcription factors and nuclear receptors (<xref rid="ref92" ref-type="bibr">Monsalve et al., 2000</xref>). The carboxy-terminal contains a well-conserved RNA recognition motif (RRM), which is involved in the binding of both RNA and single-stranded DNA. Short serine/arginine-rich stretches, called RS domains, are also located at the N-terminal of the RRM motif in PGC-1&#x003b1; (<xref rid="ref92" ref-type="bibr">Monsalve et al., 2000</xref>), and they play an important role in mRNA splicing, although their role in disease is unclear. The C-terminal region of PGC-1&#x003b1; also has a binding site for host cell factor (HCF), also known as DHDY, which synergizes with HCF to regulate the cell cycle and enhance the transcriptional activity of PGC-1&#x003b1; (<xref rid="ref75" ref-type="bibr">Lin et al., 2002</xref>). Finally, several binding sites for other coregulators, including MEF-2C, yin yang-1 (YY1), PPAR&#x003b3;, forkhead box O1 (FoxO1), mediator complex subunit 1 (MED1), and BRG1-associated factor 60a, are also located in the C-terminal region of PGC-1&#x003b1; (<xref rid="ref125" ref-type="bibr">Villena, 2015</xref>; <xref rid="ref83" ref-type="bibr">Ma et al., 2018</xref>; <xref rid="ref142" ref-type="bibr">Xin et al., 2018</xref>). The intermediate connector is a multiunit complex that is required for transcription (<xref rid="fig2" ref-type="fig">Figure 2</xref>).</p><fig position="float" id="fig2"><label>Figure 2</label><caption><p>Structure of PGC-1&#x003b1;. The amino-terminal region of PGC-1&#x003b1; functions as the surface for the recruitment of histone acyltransferase proteins. This domain contains several LXXL motifs (NR boxes), acting as coactivator signature essential for interactions with multiple types of other transcription factors and nuclear receptors. The carboxy-terminal contains RRM, which act as binding site of RNA and single-stranded DNA. The binding site for host cell factor, DHDY, synergizes with HCF to regulate the cell cycle and enhance the transcriptional activity of PGC-1&#x003b1;. Another RS domain plays an important role in mRNA splicing.</p></caption><graphic xlink:href="fnagi-16-1454735-g002" position="float"/></fig></sec><sec id="sec10"><label>4</label><title>Research progress regarding PGC-1&#x003b1; in neurological diseases</title><p>Neurons are high-energy-demanding cells, whereas PGC-1&#x003b1; is abundantly expressed in the CNS. Many studies of the role of PGC-1&#x003b1; in neurological diseases, such as ICH, ischemic stroke, AD, PD, ALS and PolyQ diseases, have been conducted. The main pathogenesis of these disorders included mitochondrial dysfunction, oxidative stress, neuroinflammation, autophagy, etc. (<xref rid="fig3" ref-type="fig">Figure 3</xref>). Therefore, we review the main roles and pathways of PGC-1&#x003b1; in neurological diseases below.</p><fig position="float" id="fig3"><label>Figure 3</label><caption><p>Mechanisms of PGC-1&#x003b1; involved in neurological diseases. Mitochondrial disorder, neuroinflammation and oxidative stress are the main pathway for PGC-1&#x003b1; amelioration of neurological disorders in Intracerebral hemorrhage (ICH) <bold>(A)</bold>, ischemic stroke <bold>(B)</bold>, Alzheimer&#x02019;s disease (AD) <bold>(C)</bold>, Huntington disease (HD) <bold>(D)</bold>, Amyotrophic lateral sclerosis (ALS) <bold>(E)</bold> and Parkinson&#x02019;s disease (PD) <bold>(F)</bold>. Repair of mitochondria mediated by PGC-1&#x003b1; plays a crucial role in the protection against ICH injury. Recent study also demonstrated that pyroptosis was another vital process for ischemic stroke. Study suggest that PGC-1&#x003b1; preventing ischemic stroke via reducing pyroptosis. PGC-1&#x003b1; could also suppress BACE1 mRNA, which is important for generation of A&#x003b2;, to protect AD. In HD, PGC-1&#x003b1; was also found to decrease aberrant aggregation and turnover of mutant HTT. The specific pathways as shown.</p></caption><graphic xlink:href="fnagi-16-1454735-g003" position="float"/></fig><sec id="sec11"><label>4.1</label><title>Intracerebral hemorrhage</title><p>Intracerebral hemorrhage (ICH) is a life-threatening disease of global importance, with poor prognosis and few efficient treatment options (<xref rid="ref22" ref-type="bibr">Cordonnier et al., 2018</xref>). Previous reports indicate that the mortality rate among ICH patients is approximately 40% within one month (<xref rid="ref121" ref-type="bibr">van Asch et al., 2010</xref>). ICH accounts for 10&#x02013;30% of all strokes, affecting more than one million people every year worldwide (<xref rid="ref34" ref-type="bibr">Feigin et al., 2003</xref>). The pathology of ICH involves mechanical disruption following initial bleeding and oxidative stress, inflammation, mitochondrial dysfunction, and neuronal death (<xref rid="ref4" ref-type="bibr">Aronowski and Zhao, 2011</xref>; <xref rid="ref147" ref-type="bibr">Yu et al., 2019</xref>). Abundant evidence supports the hypothesis that mitochondrial dysfunction occurs after ICH (<xref rid="ref138" ref-type="bibr">Wu et al., 2020</xref>; <xref rid="ref73" ref-type="bibr">Li et al., 2021</xref>), which is reportedly linked with both structural and functional disorders (<xref rid="ref156" ref-type="bibr">Zhou et al., 2017</xref>; <xref rid="ref143" ref-type="bibr">Xu et al., 2019</xref>). By injecting autologous arterial blood into rat brains, researchers found that the level of PGC-1&#x003b1; increases significantly at 1&#x0202f;h after ICH injury, reaching a peak at 72&#x0202f;h (<xref rid="ref146" ref-type="bibr">You et al., 2016</xref>). Studies in an ICH rat model showed that treatment with PGC-1<italic>&#x003b1;</italic> siRNAs significantly decreased ATP concentration, the number of mitochondria, mitochondrial proteins, and mitochondrial DNA, increased brain water content, and led to the formation of mitochondrial myelin layer structures (<xref rid="ref156" ref-type="bibr">Zhou et al., 2017</xref>). The activation or overexpression of PGC-1&#x003b1; after ICH injury promoted mitochondrial biogenesis and mitochondrial-related ROS metabolism, reduced mitochondrial dysfunction, inhibited mitochondrial-dependent cell death, and prevented the further occurrence of secondary brain injury (<xref rid="ref146" ref-type="bibr">You et al., 2016</xref>; <xref rid="ref156" ref-type="bibr">Zhou et al., 2017</xref>; <xref rid="ref58" ref-type="bibr">Jin et al., 2022</xref>). Further studies showed that PGC-1<italic>&#x003b1;</italic> alleviated mitochondrial dysfunction and secondary brain injury following ICH via AMPK- PGC-1&#x003b1; pathway (<xref rid="ref147" ref-type="bibr">Yu et al., 2019</xref>). Studies in recent years also demonstrated that PGC-1&#x003b1; involvement in mitochondrial biogenesis and antioxidative capability is protective for mice following ICH (<xref rid="ref152" ref-type="bibr">Zhang et al., 2024</xref>).</p></sec><sec id="sec12"><label>4.2</label><title>Ischemic stroke</title><p>More than 80% of strokes are ischemic and caused by an occlusion of cerebral arteries (<xref rid="ref67" ref-type="bibr">Lapchak and Zhang, 2017</xref>). Lack of blood supply results in neurons being deprived of necessary glucose and oxygen (OGD), which finally triggers pathophysiological processes including excitotoxicity, oxidative stress, inflammation, apoptosis, and cell death. Though the introduction of tissue plasminogen activator for the acute treatment of ischemic was achieved (<xref rid="ref145" ref-type="bibr">Yoshimura et al., 2018</xref>), development of neuroprotective agents for treating ischemia outside of the current narrow therapeutic window is still much more vital. There is significant experimental evidence supporting the roles of mitochondrial dysfunction and oxidative stress as determinants of neuronal death, as well as endogenous protective mechanisms after stroke (<xref rid="ref109" ref-type="bibr">St-Pierre et al., 2006</xref>; <xref rid="ref144" ref-type="bibr">Yin et al., 2008</xref>; <xref rid="ref14" ref-type="bibr">Chen et al., 2010</xref>). Several studies reveal that PGC1-&#x003b1; contributes to neuronal survival (<xref rid="ref109" ref-type="bibr">St-Pierre et al., 2006</xref>; <xref rid="ref17" ref-type="bibr">Chen et al., 2011</xref>). ROS plays a crucial role in the fate of neurons, as well as in damage progression following ischemic stroke (<xref rid="ref86" ref-type="bibr">Mattiasson et al., 2003</xref>). PGC-1&#x003b1; is a master regulator of the mitochondrial proteins SOD2 and UCP2. UCP2 and SOD2 are vital ROS-detoxifying proteins found in mitochondria. Studies revealed that the upregulation of UCP2 decreases ROS and neuronal loss in the brain tissue after cerebral ischemia (<xref rid="ref86" ref-type="bibr">Mattiasson et al., 2003</xref>; <xref rid="ref16" ref-type="bibr">Chen et al., 2006</xref>; <xref rid="ref25" ref-type="bibr">Deierborg et al., 2008</xref>). All the above information demonstrates that PGC1-&#x003b1; protects neurons from ischemic stroke by improving mitochondrial function. Advances in neuroscience have prompted further exploration of the mechanisms by which PGC-1&#x003b1; provides protection. Pyroptosis, a type of programmed cell death has been demonstrated to be involved in ischemic stroke in recent years (<xref rid="ref150" ref-type="bibr">Zhang et al., 2019</xref>). And, study found that medioresinol, a PGC-1&#x003b1; activator, ameliorated the pyroptosis of endothelial cells and ischemic brain injury via PPAR&#x003b1;-GOT1 axis (<xref rid="ref128" ref-type="bibr">Wang et al., 2021</xref>). Neferine, a bisbenzylisoquinoline alkaloids extracted from Plumula Nelumbinis.</p><p>was also found to benefit ischemia/reperfusion injury by inhibiting pyroptosis, reducing mitochondrial oxidative stress, ameliorates endothelial inflammation via regulation of PGC-1&#x003b1;/NLRP3/GSDMD signaling pathway (<xref rid="ref153" ref-type="bibr">Zheng et al., 2024</xref>). Mitophagy, which is beneficial in ischemic stroke, was also triggered by USP18/FTO via the SIRT6/AMPK/PGC-1&#x003b1;/AKT pathway in recent studies (<xref rid="ref108" ref-type="bibr">Song et al., 2024</xref>). Studies have revealed that neuroinflammation and immune responses occur minutes to hours after stroke (<xref rid="ref36" ref-type="bibr">Fu et al., 2015</xref>). PGC-1&#x003b1; in microglia could also protect against the ischemic brain injury by suppressing neuroinflammation (<xref rid="ref131" ref-type="bibr">Wang et al., 2018</xref>; <xref rid="ref43" ref-type="bibr">Han et al., 2021</xref>). Further, changes in the level of PGC-1&#x003b1; after stroke are reported for decades (<xref rid="ref120" ref-type="bibr">Valerio et al., 2011</xref>; <xref rid="ref130" ref-type="bibr">Wang et al., 2014</xref>). Therefore, targeting PGC-1&#x003b1; is a promising therapeutic strategy for ischemic stroke. Compounds and drugs targeting PGC-1&#x003b1; that have been explored for improving ischemic stroke in past decades are also collected (<xref rid="tab1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="tab1"><label>Table 1</label><caption><p>Compounds and drugs which have been found to improve ischemic stroke in past decade studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Compound/Drug</th><th align="left" valign="top" rowspan="1" colspan="1">Possible pathway</th><th align="left" valign="top" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Medioresinol</td><td align="left" valign="top" rowspan="1" colspan="1">Activating PPAR&#x003b1;-GOT1 axis</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref128" ref-type="bibr">Wang et al. (2021)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mangiferin</td><td align="left" valign="top" rowspan="1" colspan="1">Activating SIRT1/PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref9001" ref-type="bibr">Chen et al. (2021)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alpha-lipoic acid nitrone</td><td align="left" valign="top" rowspan="1" colspan="1">Up-regulating SIRT1- PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref36" ref-type="bibr">Fu et al. (2015)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dl-3n-butylphthalide</td><td align="left" valign="top" rowspan="1" colspan="1">Regulating eNOS-PGC-1&#x003b1; of endothelial</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref134" ref-type="bibr">Wei et al. (2019)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Icariin</td><td align="left" valign="top" rowspan="1" colspan="1">Increasing SIRT1/PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref157" ref-type="bibr">Zhu et al. (2010)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cerebrolysin</td><td align="left" valign="top" rowspan="1" colspan="1">Activating CREB/PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref41" ref-type="bibr">Guan et al. (2019)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Donepezil</td><td align="left" valign="top" rowspan="1" colspan="1">Activating PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref84" ref-type="bibr">Madani et al. (2021)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Naoxinqing</td><td align="left" valign="top" rowspan="1" colspan="1">Activating AMPK&#x003b1;/NAMPT/SIRT1/PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref110" ref-type="bibr">Sun et al. (2024)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3C</td><td align="left" valign="top" rowspan="1" colspan="1">Activating CaMKK&#x003b2;/AMPK/PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref131" ref-type="bibr">Wang et al. (2018)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ubiquitin-specific peptidase 18</td><td align="left" valign="top" rowspan="1" colspan="1">Activating SIRT6/AMPK/PGC-1&#x003b1;/AKT</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref108" ref-type="bibr">Song et al. (2024)</xref>
</td></tr></tbody></table></table-wrap></sec><sec id="sec13"><label>4.3</label><title>Alzheimer&#x02019;s disease</title><p>Close to 50 million people worldwide are currently suffering from dementia, including AD, whose prevalence is estimated to surpass 100 million by 2050. AD, a progressive neurodegenerative disease, is the most common form of dementia (<xref rid="ref11" ref-type="bibr">Blennow et al., 2006</xref>; <xref rid="ref1" ref-type="bibr">Alzheimer's Association, 2016</xref>). Age, family history, apolipoprotein E &#x0025b;4 genotype, hypertension, obesity, diabetes, traumatic brain injury, hyperlipidemia, and low education level are all considered risk factors for AD (<xref rid="ref11" ref-type="bibr">Blennow et al., 2006</xref>; <xref rid="ref1" ref-type="bibr">Alzheimer's Association, 2016</xref>). Synaptic dysfunction, neurotransmitter imbalance, neuroinflammation, infection, gut microbiome disruption, genetic mutations, oxidative stress, and autophagy are all potential pathogenic factors influencing AD (<xref rid="ref24" ref-type="bibr">Crews and Masliah, 2010</xref>; <xref rid="ref8" ref-type="bibr">Barage and Sonawane, 2015</xref>; <xref rid="ref35" ref-type="bibr">Ferreira-Vieira et al., 2016</xref>; <xref rid="ref26" ref-type="bibr">De-Paula et al., 2018</xref>; <xref rid="ref38" ref-type="bibr">Giau et al., 2018</xref>; <xref rid="ref5" ref-type="bibr">Ashraf et al., 2019</xref>; <xref rid="ref62" ref-type="bibr">Khan et al., 2020</xref>). Aggregation of A<italic>&#x003b2;</italic> peptides in neuritic plaques and neurofibrillary tangles (NFTs) of hyperphosphorylated Tau protein are pathological features of AD (<xref rid="ref2" ref-type="bibr">Amemori et al., 2015</xref>). Generation of A&#x003b2; depends on the sequential proteolytic cleavage of the amyloid precursor protein (APP) by &#x003b2;-secretase 1 (BACE1) and the <italic>&#x003b3;</italic>-secretase complex (<xref rid="ref45" ref-type="bibr">Hardy and Selkoe, 2002</xref>). APP/PS1 mutated mice are classical models for AD investigation, with research showing that enhanced PGC-1<italic>&#x003b1;</italic> mRNA levels caused by decreased function of PS1 may be involved in the pathogenesis of this research model (<xref rid="ref102" ref-type="bibr">Robinson et al., 2014</xref>). Given that BACE1 is the rate-limiting enzyme in A&#x003b2; generation and APP processing, it is suggested to be one of the most important therapeutic targets for treating AD. PGC-1&#x003b1; is shown to decrease in the brains of AD patients (<xref rid="ref148" ref-type="bibr">Zehnder et al., 2021</xref>). Studies revealed that overexpression of PGC-1&#x003b1; suppressed the basal transcription of endogenous BACE1 mRNA (<xref rid="ref129" ref-type="bibr">Wang et al., 2013</xref>),which further explains the phenomenon that levels of PGC-1&#x003b1; protein are inversely linked to both AD-type neuritic plaque abnormalities and A&#x003b2; content (<xref rid="ref99" ref-type="bibr">Pohland et al., 2018</xref>). Further research showed that the effect of PGC-1 on BACE1 requires deacetylation by SIRT1 (<xref rid="ref129" ref-type="bibr">Wang et al., 2013</xref>), and it has also been demonstrated that metabolic stress modulates Alzheimer&#x02019;s &#x003b2;-secretase gene transcription via action on the SIRT1-PPAR<italic>&#x003b3;</italic>-PGC-1 pathway. Mitochondrial dysfunction is a pivotal event in AD pathogenesis (<xref rid="ref98" ref-type="bibr">Panes et al., 2020</xref>). Repairment of mitophagy and mitochondrial biogenesis ameliorated AD via PINK1/LC3B/P62 and PGC-1<italic>&#x003b1;</italic>/Nrf2 in one study of Lithospermic acid B (<xref rid="ref90" ref-type="bibr">Meng et al., 2024</xref>). SIRT1/PGC-1&#x003b1; signaling pathway, which reduces oxidative stress, was also found to attenuate cognitive deficits in Alzheimer&#x02019;s disease (<xref rid="ref78" ref-type="bibr">Liu et al., 2023</xref>). Neuroinflammation is also known to influence A&#x003b2; plaques and NFT. Indeed, many studies support the idea that A&#x003b2; plaques and neuroinflammation form a positive feedback loop in AD (<xref rid="ref28" ref-type="bibr">Doig, 2018</xref>). One study found that resveratrol (RSV) reduced inflammatory cytokine release, improved mitochondrial bioenergetics, and ameliorated A&#x003b2;-peptide clearance by activating SIRT1 and AMPK (<xref rid="ref101" ref-type="bibr">Price et al., 2012</xref>). The latter functions in the AMPK/SIRT1/PGC-1&#x003b1; pathway, a canonical signaling cascade influencing cell survival (<xref rid="ref116" ref-type="bibr">Tian et al., 2019</xref>; <xref rid="ref151" ref-type="bibr">Zhang and Wu, 2021</xref>). PGC-1&#x003b1; as the media of regulation mitochondrial biogenesis, mitophagy, neuroinflammation and A&#x003b2; generation involved in the pathogenesis and neuroprotection of AD.</p></sec><sec id="sec14"><label>4.4</label><title>Parkinson&#x02019;s disease</title><p>PD is one of the most common neurodegenerative disorders worldwide, and the number of people suffering from this disorder has more than doubled in the last 30&#x0202f;years. The pathological features of PD include the progressive loss of dopaminergic neurons (<xref rid="ref88" ref-type="bibr">Meara, 1994</xref>). The possible pathophysiologic mechanisms underlying PD include &#x003b1;-synuclein misfolding and aggregation, mitochondrial dysfunction, impairment of protein clearance, neuroinflammation, and oxidative stress (<xref rid="ref51" ref-type="bibr">Jankovic and Tan, 2020</xref>). The involvement of mitochondrial disorders in PD was first established more than three decades ago. In 1983, researchers found that the administration of 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) led to parkinsonism in both animal models and humans through metabolite ion MPP+ activation and the subsequent inhibition of multiple complexes of the respiratory chain (<xref rid="ref66" ref-type="bibr">Langston and Ballard, 1983</xref>; <xref rid="ref105" ref-type="bibr">Schapira et al., 1989</xref>; <xref rid="ref40" ref-type="bibr">Grunewald et al., 2019</xref>). Subsequent research achieved significant progress regarding the elucidation of the monogenic causes of PD associated with mitochondrial dysfunction. These genes include SNCA (<xref rid="ref100" ref-type="bibr">Polymeropoulos et al., 1997</xref>), LRRK2 (<xref rid="ref97" ref-type="bibr">Paisan-Ruiz et al., 2004</xref>), VPS35 (<xref rid="ref114" ref-type="bibr">Tang et al., 2015</xref>), CHCHD2 (<xref rid="ref37" ref-type="bibr">Funayama et al., 2015</xref>), Parkin, PINK1, and DJ-1. Another study of MPTP found that LSN862 (LSN), a novel non-thiazolidinedione partial PPAR- &#x003b3; agonist, exerted neuroprotective effects in a mouse model of PD by increasing PPAR- &#x003b3; and PGC1-&#x003b1; expression (<xref rid="ref112" ref-type="bibr">Swanson et al., 2013</xref>). AMPK/SIRT-1/PGC-1&#x003b1;-mediated autophagy (<xref rid="ref69" ref-type="bibr">Lee et al., 2023</xref>; <xref rid="ref30" ref-type="bibr">Elesawy et al., 2024</xref>), mitochondrial biogenesis (<xref rid="ref77" ref-type="bibr">Liu et al., 2022</xref>; <xref rid="ref55" ref-type="bibr">Jhuo et al., 2024</xref>) PGC-1&#x003b1;/Nrf mediated oxidative stress (<xref rid="ref42" ref-type="bibr">Guo et al., 2023</xref>) were all classical pathway in PD. Research further identified many molecules and drugs that can ameliorate PD (<xref rid="tab2" ref-type="table">Table 2</xref>). For example, findings in a 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD revealed that ferulic acid reduced mitochondrial Drp1 and increased PGC1&#x003b1;, restoring mitochondrial dynamics in lesioned animals (<xref rid="ref3" ref-type="bibr">Anis et al., 2020</xref>). PGC-1&#x003b1; also protects neurons in PD from neuroinflammation (<xref rid="ref91" ref-type="bibr">Mohammed et al., 2024</xref>). Previous work also found that <italic>L. plantarum</italic> DP189 activated the (Nrf2)/ARE and PGC-1&#x003b1; pathways and suppressed the NLRP3 inflammasome in PD mice (<xref rid="ref133" ref-type="bibr">Wang L. et al., 2022</xref>). To date, the study of mitochondria dysfunction and the methods to reverse this disorder play major role in the field of PD research. Moreover, additional studies on other physiological processes of PD are also needed.</p><table-wrap position="float" id="tab2"><label>Table 2</label><caption><p>Compounds and drugs which have been found to improve PD in past decade studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Compound/Drug</th><th align="left" valign="top" rowspan="1" colspan="1">Possible pathway</th><th align="left" valign="top" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Empagliflozin</td><td align="left" valign="top" rowspan="1" colspan="1">Activating AMPK/SIRT-1/PGC-1 and wnt/&#x003b2;-catenin</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref91" ref-type="bibr">Mohammed et al. (2024)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Farnesol</td><td align="left" valign="top" rowspan="1" colspan="1">Enhancing farnesylation of PARIS and restoring PGC-1&#x003b1; activity</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref59" ref-type="bibr">Jo et al. (2021)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tetramethylpyrazine nitrone</td><td align="left" valign="top" rowspan="1" colspan="1">Activating PGC-1&#x003b1;/Nrf2</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref42" ref-type="bibr">Guo et al. (2023)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">liraglutide</td><td align="left" valign="top" rowspan="1" colspan="1">Upregulating PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref139" ref-type="bibr">Wu et al. (2022)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Roflupram</td><td align="left" valign="top" rowspan="1" colspan="1">Activating CREB/PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref154" ref-type="bibr">Zhong et al. (2020)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6-Hydroxydopamine</td><td align="left" valign="top" rowspan="1" colspan="1">Activating PKA/Akt/GSK-3&#x003b2; and CREB/PGC-1&#x003b1;/NRF-1/TFAM</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref155" ref-type="bibr">Zhou et al. (2019)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Urolithin A</td><td align="left" valign="top" rowspan="1" colspan="1">Activating SIRT1-PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref77" ref-type="bibr">Liu et al. (2022)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alpha-lipoic acid (ALA)</td><td align="left" valign="top" rowspan="1" colspan="1">Upregulating Sirt1/PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref149" ref-type="bibr">Zhang et al. (2022)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Teaghrelin</td><td align="left" valign="top" rowspan="1" colspan="1">Activating AMPK/SIRT1/PGC-1&#x003b1; and ERK1/2</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref55" ref-type="bibr">Jhuo et al. (2024)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fucoidan</td><td align="left" valign="top" rowspan="1" colspan="1">Activating AMPK-PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref44" ref-type="bibr">Han et al. (2019)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Garcinol</td><td align="left" valign="top" rowspan="1" colspan="1">DJ-1/SIRT1/PGC-1/ p-AMPK</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref69" ref-type="bibr">Lee et al. (2023)</xref>
</td></tr></tbody></table></table-wrap></sec><sec id="sec15"><label>4.5</label><title>Amyotrophic lateral sclerosis</title><p>ALS is a fatal neurodegenerative disease. As a rare and poorly characterized disorder, it is difficult to diagnose. The lifetime risk of ALS is high, with approximately 1 in 350 people ultimately developing the disease, although limited life expectancy reduces the prevalence (<xref rid="ref104" ref-type="bibr">Ryan et al., 2019</xref>). As a combination disorder of upper and lower motor neurons, ALS presents as progressive weakness of the voluntary skeletal muscles involved in limb movement, swallowing (dysphagia), speaking (dysarthria), and respiratory function, with heterogeneous clinical presentations. Unlike other neurodegenerative diseases, the pathogenesis of ALS remains ambiguous, and the pathogenic genes are complex. Although the frequency of genetic subtypes does vary by race, the most common mutations are found in C9orf72, TARDBP, SOD1, and FUS (<xref rid="ref107" ref-type="bibr">Smith et al., 2013</xref>). Studies support the hypothesis that impaired RNA metabolism, altered proteostasis, autophagy, trafficking defects, and mitochondrial dysfunction are the primary pathological processes underlying ALS (<xref rid="ref94" ref-type="bibr">Nguyen et al., 2018</xref>). As an indispensable molecule for cells, PGC-1&#x003b1; is decreased in the CNS due to mutations in SOD1 and FUS/TLS in two mouse models of familial ALS (<xref rid="ref115" ref-type="bibr">Thau et al., 2012</xref>; <xref rid="ref10" ref-type="bibr">Bayer et al., 2017</xref>). Lactate-induced CNS-specific PGC-1&#x003b1; pathway activation was also completely absent in ALS patient-derived motoneurons with two different frame-shift FUS/TLS mutations (<xref rid="ref10" ref-type="bibr">Bayer et al., 2017</xref>). PGC-1&#x003b1; was also considered a male-dominant disease modifier of ALS (<xref rid="ref31" ref-type="bibr">Eschbach et al., 2013</xref>). Increasing mitochondrial mass through PGC-1&#x003b1; over-expression led to protection against ALS neurodegeneration as shown (<xref rid="ref124" ref-type="bibr">Varghese et al., 2020</xref>). Research in the SOD1<sup>G93A</sup> ALS mouse model showed that activation of PGC-1&#x003b1;/Nrf2/HO-1 pathway increased mitochondrial antioxidant activity and decreased expression of human SOD1 (<xref rid="ref135" ref-type="bibr">Wen et al., 2021</xref>), one pathogenic protein of ALS. AMPK/PGC-1&#x003b1;/Nrf1/Tfam activation promotes mitochondrial biogenesis and ameliorates mitochondrial dysfunction, which was also verified in SOD1<sup>G93A</sup> mice. Indeed, numerous studies have identified several molecules/drugs which can treat ALS by modulating the PGC-1&#x003b1; pathway (<xref rid="tab3" ref-type="table">Table 3</xref>), which offers a promising prospect for targeting PGC-1&#x003b1; as effective treatment strategies.</p><table-wrap position="float" id="tab3"><label>Table 3</label><caption><p>Compounds and drugs which have been found to improve ALS in past decade studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Compound/Drug</th><th align="left" valign="top" rowspan="1" colspan="1">Possible pathway</th><th align="left" valign="top" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">R13, a prodrug of 7,8-dihydroxyflavone</td><td align="left" valign="top" rowspan="1" colspan="1">Activating AMPK/PGC-1&#x003b1;/Nrf1/Tfam</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref73" ref-type="bibr">Li et al. (2021)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tetramethylpyrazine nitrone</td><td align="left" valign="top" rowspan="1" colspan="1">Activating PGC-1&#x003b1;/Nrf2/HO-1</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref135" ref-type="bibr">Wen et al. (2021)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tetramethylpyrazine nitrone</td><td align="left" valign="top" rowspan="1" colspan="1">Activating Akt/mTOR/GSK-3&#x003b2; and AMPK/PGC-1&#x003b1;/Nrf2</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref48" ref-type="bibr">Huang et al. (2021)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VAR10303</td><td align="left" valign="top" rowspan="1" colspan="1">Upregulating PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref39" ref-type="bibr">Golko-Perez et al. (2017)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oxaloacetate</td><td align="left" valign="top" rowspan="1" colspan="1">Increase TNF&#x003b1; andPGC-1&#x003b1; mRNAs</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref119" ref-type="bibr">Tungtur et al. (2021)</xref>
</td></tr></tbody></table></table-wrap></sec><sec id="sec16"><label>4.6</label><title>Huntington&#x02019;s disease</title><p>HD is an autosomal dominant neurodegenerative disease caused by the expansion of CAG repeats in the first exon of the HTT gene, encoding a mutant Huntington (mHTT) protein (<xref rid="ref68" ref-type="bibr">Leavitt et al., 2020</xref>). HD is characterized by atrophy of the basal ganglia nuclei and subcortical white matter, and its associated symptoms include motor, psychiatric, and cognitive deficits, which generally present in middle age and are gradually progressive (<xref rid="ref113" ref-type="bibr">Tabrizi et al., 2019</xref>). There is still no effective treatment for HD. A toxic gain-of-function of the mHTT protein, caused by expanded PolyQ, has been proposed as a driving factor in HD, which functions by leading to neuronal loss. The mechanisms underlying the disease are complex, including deregulation of the ubiquitin, proteasome, and autophagy systems, as well as oxidative stress (<xref rid="ref57" ref-type="bibr">Jimenez-Sanchez et al., 2017</xref>). Recently, mitochondrial dysfunction was identified as a key contributor to HD pathology (<xref rid="ref64" ref-type="bibr">Kumar and Ratan, 2016</xref>; <xref rid="ref122" ref-type="bibr">van Well et al., 2019</xref>; <xref rid="ref61" ref-type="bibr">Jurcau and Jurcau, 2023</xref>). Studies in HD animal models and the striatal tissues of patients have shown that transcriptional dysregulation of PGC-1&#x003b1; is involved in the neurodegeneration of HD (<xref rid="ref137" ref-type="bibr">Weydt et al., 2009</xref>; <xref rid="ref65" ref-type="bibr">La Spada, 2012</xref>). Transcription and mitochondrial dysfunction caused by alteration in PGC-1&#x003b1; were also documented in HD (<xref rid="ref136" ref-type="bibr">Weydt et al., 2006</xref>). Though most studies support that energy failure is involved in the role of PGC-1&#x003b1; disorder in HD, disruption of ribosomal transcription by PGC-1&#x003b1; was also identified in HD (<xref rid="ref53" ref-type="bibr">Jesse et al., 2017</xref>). On the other hand, the role of CREB in the regulation of PGC-1&#x003b1; in neurons in response to oxidative stress was studied (<xref rid="ref109" ref-type="bibr">St-Pierre et al., 2006</xref>). PGC-1&#x003b1; promoter binding with less HSF1 in a cell culture model of HD demonstrated the destruction of the heat shock response in HD (<xref rid="ref50" ref-type="bibr">Intihar et al., 2019</xref>). Less activation of HSF1 in this model exacerbates cell death (<xref rid="ref50" ref-type="bibr">Intihar et al., 2019</xref>). The role of PGC-1&#x003b1; in the pathogenesis of HD was further verified by PGC-1&#x003b1; KO models emulating the main characteristics of HD (<xref rid="ref76" ref-type="bibr">Lin et al., 2004</xref>; <xref rid="ref53" ref-type="bibr">Jesse et al., 2017</xref>). Crossing N171-82Q HD transgenic mice with inducible TRE-PGC-1&#x003b1; mice decreased aberrant aggregation and turnover of mutant HTT, mitigated striatal neurodegeneration, and improved mitochondrial dysfunction observed in HD mice (<xref rid="ref118" ref-type="bibr">Tsunemi et al., 2012</xref>). Several drugs and compounds ameliorating the phenotype of HD via regulating PGC-1&#x003b1; have also been identified in recent decades (<xref rid="tab4" ref-type="table">Table 4</xref>).</p><table-wrap position="float" id="tab4"><label>Table 4</label><caption><p>Compounds and drugs which have been found to improve HD in past decade studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Compound/Drug</th><th align="left" valign="top" rowspan="1" colspan="1">Possible pathway</th><th align="left" valign="top" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Morin hydrate</td><td align="left" valign="top" rowspan="1" colspan="1">Enhancing p-PGC-1&#x003b1; and p-VDAC1</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref29" ref-type="bibr">El-Emam et al. (2024)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ginsenoside Rg3 and Rf</td><td align="left" valign="top" rowspan="1" colspan="1">Increase PGC-1&#x003b1; and p-CREB</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref71" ref-type="bibr">Lee et al. (2021)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Beta-Lapachone</td><td align="left" valign="top" rowspan="1" colspan="1">Activating Sirt1/p-CREB/ PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref70" ref-type="bibr">Lee et al. (2018)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Resveratrol</td><td align="left" valign="top" rowspan="1" colspan="1">Activating PGC-1&#x003b1;/TFAM</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref93" ref-type="bibr">Naia et al. (2017)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Epoxyeicosatrienoic acid</td><td align="left" valign="top" rowspan="1" colspan="1">Increase PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref126" ref-type="bibr">Waldman et al. (2016)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Metformin</td><td align="left" valign="top" rowspan="1" colspan="1">Increase PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref27" ref-type="bibr">Di Cristo et al. (2019)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bezafibrate</td><td align="left" valign="top" rowspan="1" colspan="1">Increase PGC-1&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref12" ref-type="bibr">Chandra et al. (2016)</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Teaghrelin</td><td align="left" valign="top" rowspan="1" colspan="1">Activating AMPK/SIRT1/PGC-1&#x003b1; and ERK1/2</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ref55" ref-type="bibr">Jhuo et al. (2024)</xref>
</td></tr></tbody></table></table-wrap></sec><sec id="sec17"><label>4.7</label><title>Other PolyQ diseases</title><p>Spinocerebellar ataxia 3 (SCA3), which is one of the nine identified PolyQ diseases, is a rare, inherited neurodegenerative disease. As the second most prevalent disease in the PolyQ group, SCA3 affects about 1&#x02013;5 in every 100,000 people globally (<xref rid="ref72" ref-type="bibr">Li et al., 2018</xref>). Mitochondrial dysfunction, metabolic abnormalities, autophagy and oxidative stress have been shown to be involved in the pathogenesis of SCA3. As a vital molecule controlling mitochondrial biogenesis, PGC-1&#x003b1; has also been demonstrated to ameliorate SCA3. Glycyrrhiza inflata herb extract and its constituents, licochalcone A and ammonium glycyrrhizinate, increased mitochondrial biogenesis, decreased oxidative stress, and reduced aggregate formation in SCA3 cellular models via the activation of PGC-1&#x003b1; and NRF2-ARE (<xref rid="ref15" ref-type="bibr">Chen et al., 2014</xref>). Further, SG-Tang has been proven to exert protective effects against SCA17, another PolyQ disease characterized by progressive ataxia, seizures, cognitive dysfunction, psychiatric symptoms, and pyramidal/extrapyramidal signs via upregulating the PGC-1&#x003b1;/SOD2/CYCS, NRF2/GCLC/NQO1, and NFYA/HSPA5 pathways (<xref rid="ref13" ref-type="bibr">Chen et al., 2019</xref>). Although studies of PGC-1&#x003b1; in other PolyQ diseases are limited, research in this field is ongoing and has yet to be fully explored.</p></sec></sec><sec sec-type="conclusions" id="sec18"><label>5</label><title>Conclusion</title><p>Neurological diseases are the leading cause of disability and the second leading cause of death worldwide. With population aging, the number of patients suffering from neurological disease is rising. While stroke remains the most common neurological disease, morbidity related to neurodegenerative diseases, such as AD and PD, is becoming increasingly common. The incidences of hereditary neurological diseases, like HD, SCA (SCA1, SCA2, SCA3, SCA7, SCA36, etc) are also increasing year by year. Reducing morbidity and increasing effective therapeutic strategies for neurological disorders are therefore urgently needed.</p><p>In this review, we highlight the role of PGC-1&#x003b1; in the nervous system and neurological diseases such as stroke, AD, PD, ALS, and PolyQ diseases. A review of the existing literature suggests that PGC-1&#x003b1; overexpression could be a potential therapeutic target for these types of diseases. However, almost all studies upregulated PGC-1&#x003b1; via gene transfection and compound drugs <italic>in vitro</italic> or <italic>in vivo</italic> animal models. Whether PGC-1&#x003b1; supplementation and which compounds could open promising avenues for neuroprotective therapeutics among neurological diseases, or even within a specific neurological disease, merits further rigorous preclinical studies and decisive evaluation through clinical trials.</p></sec></body><back><sec sec-type="author-contributions" id="sec19"><title>Author contributions</title><p>M-bT: Formal analysis, Funding acquisition, Supervision, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. Y-xL: Writing &#x02013; review &#x00026; editing, Formal analysis, Methodology. Z-wH: Methodology, Writing &#x02013; original draft. H-yL: Formal analysis, Writing &#x02013; review &#x00026; editing. SZ: Methodology, Writing &#x02013; original draft. C-hS: Supervision, Writing &#x02013; review &#x00026; editing. Y-mX: Investigation, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="sec21"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="sec22"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab id="coll1">Alzheimer's Association</collab></person-group> (<year>2016</year>). <article-title>2016 Alzheimer's disease facts and figures</article-title>. <source>Alzheimer&#x02019;s Dement</source>
<volume>12</volume>, <fpage>459</fpage>&#x02013;<lpage>509</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jalz.2016.03.001</pub-id><pub-id pub-id-type="pmid">27570871</pub-id>
</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amemori</surname><given-names>T.</given-names></name><name><surname>Jendelova</surname><given-names>P.</given-names></name><name><surname>Ruzicka</surname><given-names>J.</given-names></name><name><surname>Urdzikova</surname><given-names>L. M.</given-names></name><name><surname>Sykova</surname><given-names>E.</given-names></name></person-group> (<year>2015</year>). <article-title>Alzheimer's disease: mechanism and approach to cell therapy</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>16</volume>, <fpage>26417</fpage>&#x02013;<lpage>26451</lpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms161125961</pub-id>, PMID: <pub-id pub-id-type="pmid">26556341</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anis</surname><given-names>E.</given-names></name><name><surname>Zafeer</surname><given-names>M. F.</given-names></name><name><surname>Firdaus</surname><given-names>F.</given-names></name><name><surname>Islam</surname><given-names>S. N.</given-names></name><name><surname>Anees</surname><given-names>K. A.</given-names></name><name><surname>Ali</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Ferulic acid reinstates mitochondrial dynamics through PGC1alpha expression modulation in 6-hydroxydopamine lesioned rats</article-title>. <source>Phytother. Res.</source>
<volume>34</volume>, <fpage>214</fpage>&#x02013;<lpage>226</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ptr.6523</pub-id>, PMID: <pub-id pub-id-type="pmid">31657074</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aronowski</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name></person-group> (<year>2011</year>). <article-title>Molecular pathophysiology of cerebral hemorrhage: secondary brain injury</article-title>. <source>Stroke</source>
<volume>42</volume>, <fpage>1781</fpage>&#x02013;<lpage>1786</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.110.596718</pub-id>, PMID: <pub-id pub-id-type="pmid">21527759</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashraf</surname><given-names>G. M.</given-names></name><name><surname>Tarasov</surname><given-names>V. V.</given-names></name><name><surname>Makhmutovsmall</surname><given-names>A.</given-names></name><name><surname>Chubarev</surname><given-names>V. N.</given-names></name><name><surname>Avila-Rodriguez</surname><given-names>M.</given-names></name><name><surname>Bachurin</surname><given-names>S. O.</given-names></name></person-group> (<year>2019</year>). <article-title>The possibility of an infectious Etiology of Alzheimer disease</article-title>. <source>Mol. Neurobiol.</source>
<volume>56</volume>, <fpage>4479</fpage>&#x02013;<lpage>4491</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-018-1388-y</pub-id>, PMID: <pub-id pub-id-type="pmid">30338482</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustyniak</surname><given-names>J.</given-names></name><name><surname>Lenart</surname><given-names>J.</given-names></name><name><surname>Gaj</surname><given-names>P.</given-names></name><name><surname>Kolanowska</surname><given-names>M.</given-names></name><name><surname>Jazdzewski</surname><given-names>K.</given-names></name><name><surname>Stepien</surname><given-names>P. P.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Bezafibrate upregulates mitochondrial biogenesis and influence neural differentiation of human-induced pluripotent stem cells</article-title>. <source>Mol. Neurobiol.</source>
<volume>56</volume>, <fpage>4346</fpage>&#x02013;<lpage>4363</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-018-1368-2</pub-id>, PMID: <pub-id pub-id-type="pmid">30315479</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayasolla</surname><given-names>K. R.</given-names></name><name><surname>Singh</surname><given-names>A. K.</given-names></name><name><surname>Singh</surname><given-names>I.</given-names></name></person-group> (<year>2005</year>). <article-title>5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) attenuates the expression of LPS- and Abeta peptide-induced inflammatory mediators in astroglia</article-title>. <source>J. Neuroinflamm.</source>
<volume>2</volume>:<fpage>21</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1742-2094-2-21</pub-id>, PMID: <pub-id pub-id-type="pmid">16174294</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barage</surname><given-names>S. H.</given-names></name><name><surname>Sonawane</surname><given-names>K. D.</given-names></name></person-group> (<year>2015</year>). <article-title>Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer's disease</article-title>. <source>Neuropeptides</source>
<volume>52</volume>, <fpage>1</fpage>&#x02013;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.npep.2015.06.008</pub-id>, PMID: <pub-id pub-id-type="pmid">26149638</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartley</surname><given-names>A. F.</given-names></name><name><surname>Lucas</surname><given-names>E. K.</given-names></name><name><surname>Brady</surname><given-names>L. J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Hablitz</surname><given-names>J. J.</given-names></name><name><surname>Cowell</surname><given-names>R. M.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Interneuron transcriptional dysregulation causes frequency-dependent alterations in the balance of inhibition and excitation in hippocampus</article-title>. <source>J. Neurosci.</source>
<volume>35</volume>, <fpage>15276</fpage>&#x02013;<lpage>15290</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1834-15.2015</pub-id>, PMID: <pub-id pub-id-type="pmid">26586816</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayer</surname><given-names>H.</given-names></name><name><surname>Lang</surname><given-names>K.</given-names></name><name><surname>Buck</surname><given-names>E.</given-names></name><name><surname>Higelin</surname><given-names>J.</given-names></name><name><surname>Barteczko</surname><given-names>L.</given-names></name><name><surname>Pasquarelli</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>ALS-causing mutations differentially affect PGC-1alpha expression and function in the brain vs. peripheral tissues</article-title>. <source>Neurobiol. Dis.</source>
<volume>97</volume>, <fpage>36</fpage>&#x02013;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2016.11.001</pub-id>, PMID: <pub-id pub-id-type="pmid">27818323</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K.</given-names></name><name><surname>de Leon</surname><given-names>M. J.</given-names></name><name><surname>Zetterberg</surname><given-names>H.</given-names></name></person-group> (<year>2006</year>). <article-title>Alzheimer's disease</article-title>. <source>Lancet</source>
<volume>368</volume>, <fpage>387</fpage>&#x02013;<lpage>403</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(06)69113-7</pub-id>, PMID: <pub-id pub-id-type="pmid">16876668</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>A.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Calingasan</surname><given-names>N. Y.</given-names></name><name><surname>White</surname><given-names>J. M.</given-names></name><name><surname>Shurubor</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>X. W.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length&#x0202f;mouse model of Huntington's disease</article-title>. <source>Hum. Mol. Genet.</source>
<volume>25</volume>, <fpage>2269</fpage>&#x02013;<lpage>2282</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddw095</pub-id><pub-id pub-id-type="pmid">27008868</pub-id>
</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C. M.</given-names></name><name><surname>Chen</surname><given-names>W. L.</given-names></name><name><surname>Hung</surname><given-names>C. T.</given-names></name><name><surname>Lin</surname><given-names>T. H.</given-names></name><name><surname>Lee</surname><given-names>M. C.</given-names></name><name><surname>Chen</surname><given-names>I. C.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models</article-title>. <source>Aging</source>
<volume>11</volume>, <fpage>986</fpage>&#x02013;<lpage>1007</lpage>. doi: <pub-id pub-id-type="doi">10.18632/aging.101804</pub-id>, PMID: <pub-id pub-id-type="pmid">30760647</pub-id>
</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S. D.</given-names></name><name><surname>Lin</surname><given-names>T. K.</given-names></name><name><surname>Yang</surname><given-names>D. I.</given-names></name><name><surname>Lee</surname><given-names>S. Y.</given-names></name><name><surname>Shaw</surname><given-names>F. Z.</given-names></name><name><surname>Liou</surname><given-names>C. W.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Protective effects of peroxisome proliferator-activated receptors gamma coactivator-1alpha against neuronal cell death in the hippocampal CA1 subfield after transient global ischemia</article-title>. <source>J. Neurosci. Res.</source>
<volume>88</volume>, <fpage>605</fpage>&#x02013;<lpage>613</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jnr.22225</pub-id>, PMID: <pub-id pub-id-type="pmid">19774674</pub-id>
</mixed-citation></ref><ref id="ref9001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Ji</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>SIRT1/PGC-1alpha signaling activation by mangiferin attenuates cerebral hypoxia/reoxygenation injury in neuroblastoma cells</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>907</volume>:<fpage>174236</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejphar.2021.174236</pub-id><pub-id pub-id-type="pmid">34116043</pub-id>
</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C. M.</given-names></name><name><surname>Weng</surname><given-names>Y. T.</given-names></name><name><surname>Chen</surname><given-names>W. L.</given-names></name><name><surname>Lin</surname><given-names>T. H.</given-names></name><name><surname>Chao</surname><given-names>C. Y.</given-names></name><name><surname>Lin</surname><given-names>C. H.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Aqueous extract of Glycyrrhiza inflata inhibits aggregation by upregulating PPARGC1A and NFE2L2-ARE pathways in cell models of spinocerebellar ataxia 3</article-title>. <source>Free Radic. Biol. Med.</source>
<volume>71</volume>, <fpage>339</fpage>&#x02013;<lpage>350</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.03.023</pub-id>, PMID: <pub-id pub-id-type="pmid">24675225</pub-id>
</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S. D.</given-names></name><name><surname>Wu</surname><given-names>H. Y.</given-names></name><name><surname>Yang</surname><given-names>D. I.</given-names></name><name><surname>Lee</surname><given-names>S. Y.</given-names></name><name><surname>Shaw</surname><given-names>F. Z.</given-names></name><name><surname>Lin</surname><given-names>T. K.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Effects of rosiglitazone on global ischemia-induced hippocampal injury and expression of mitochondrial uncoupling protein 2</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>351</volume>, <fpage>198</fpage>&#x02013;<lpage>203</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2006.10.017</pub-id>, PMID: <pub-id pub-id-type="pmid">17052689</pub-id>
</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S. D.</given-names></name><name><surname>Yang</surname><given-names>D. I.</given-names></name><name><surname>Lin</surname><given-names>T. K.</given-names></name><name><surname>Shaw</surname><given-names>F. Z.</given-names></name><name><surname>Liou</surname><given-names>C. W.</given-names></name><name><surname>Chuang</surname><given-names>Y. C.</given-names></name></person-group> (<year>2011</year>). <article-title>Roles of oxidative stress, apoptosis, PGC-1alpha and mitochondrial biogenesis in cerebral ischemia</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>12</volume>, <fpage>7199</fpage>&#x02013;<lpage>7215</lpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms12107199</pub-id>, PMID: <pub-id pub-id-type="pmid">22072942</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>A.</given-names></name><name><surname>Wan</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>J. L.</given-names></name><name><surname>Kamimura</surname><given-names>N.</given-names></name><name><surname>Son</surname><given-names>T. G.</given-names></name><name><surname>Ouyang</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Involvement of PGC-1alpha in the formation and maintenance of neuronal dendritic spines</article-title>. <source>Nat. Commun.</source>
<volume>3</volume>:<fpage>1250</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms2238</pub-id>, PMID: <pub-id pub-id-type="pmid">23212379</pub-id>
</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciron</surname><given-names>C.</given-names></name><name><surname>Lengacher</surname><given-names>S.</given-names></name><name><surname>Dusonchet</surname><given-names>J.</given-names></name><name><surname>Aebischer</surname><given-names>P.</given-names></name><name><surname>Schneider</surname><given-names>B. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Sustained expression of PGC-1alpha in the rat nigrostriatal system selectively impairs dopaminergic function</article-title>. <source>Hum. Mol. Genet.</source>
<volume>21</volume>, <fpage>1861</fpage>&#x02013;<lpage>1876</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddr618</pub-id>, PMID: <pub-id pub-id-type="pmid">22246294</pub-id>
</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciron</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Bobela</surname><given-names>W.</given-names></name><name><surname>Knott</surname><given-names>G. W.</given-names></name><name><surname>Leone</surname><given-names>T. C.</given-names></name><name><surname>Kelly</surname><given-names>D. P.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>PGC-1alpha activity in nigral dopamine neurons determines vulnerability to alpha-synuclein</article-title>. <source>Acta Neuropathol. Commun.</source>
<volume>3</volume>:<fpage>16</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40478-015-0200-8</pub-id>, PMID: <pub-id pub-id-type="pmid">25853296</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>J.</given-names></name><name><surname>Silvaggi</surname><given-names>J. M.</given-names></name><name><surname>Kiselak</surname><given-names>T.</given-names></name><name><surname>Zheng</surname><given-names>K.</given-names></name><name><surname>Clore</surname><given-names>E. L.</given-names></name><name><surname>Dai</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Pgc-1alpha overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf</article-title>. <source>PLoS One</source>
<volume>7</volume>:<fpage>e48925</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0048925</pub-id>, PMID: <pub-id pub-id-type="pmid">23145024</pub-id>
</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordonnier</surname><given-names>C.</given-names></name><name><surname>Demchuk</surname><given-names>A.</given-names></name><name><surname>Ziai</surname><given-names>W.</given-names></name><name><surname>Anderson</surname><given-names>C. S.</given-names></name></person-group> (<year>2018</year>). <article-title>Intracerebral haemorrhage: current approaches to acute management</article-title>. <source>Lancet</source>
<volume>392</volume>, <fpage>1257</fpage>&#x02013;<lpage>1268</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(18)31878-6</pub-id>, PMID: <pub-id pub-id-type="pmid">30319113</pub-id>
</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowell</surname><given-names>R. M.</given-names></name><name><surname>Blake</surname><given-names>K. R.</given-names></name><name><surname>Russell</surname><given-names>J. W.</given-names></name></person-group> (<year>2007</year>). <article-title>Localization of the transcriptional coactivator PGC-1alpha to GABAergic neurons during maturation of the rat brain</article-title>. <source>J. Comp. Neurol.</source>
<volume>502</volume>, <fpage>1</fpage>&#x02013;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cne.21211</pub-id>, PMID: <pub-id pub-id-type="pmid">17335037</pub-id>
</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crews</surname><given-names>L.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>). <article-title>Molecular mechanisms of neurodegeneration in Alzheimer's disease</article-title>. <source>Hum. Mol. Genet.</source>
<volume>19</volume>, <fpage>R12</fpage>&#x02013;<lpage>R20</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddq160</pub-id>, PMID: <pub-id pub-id-type="pmid">20413653</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deierborg</surname><given-names>T.</given-names></name><name><surname>Wieloch</surname><given-names>T.</given-names></name><name><surname>Diano</surname><given-names>S.</given-names></name><name><surname>Warden</surname><given-names>C. H.</given-names></name><name><surname>Horvath</surname><given-names>T. L.</given-names></name><name><surname>Mattiasson</surname><given-names>G.</given-names></name></person-group> (<year>2008</year>). <article-title>Overexpression of UCP2 protects thalamic neurons following global ischemia in the mouse</article-title>. <source>J. Cereb. Blood Flow Metab.</source>
<volume>28</volume>, <fpage>1186</fpage>&#x02013;<lpage>1195</lpage>. doi: <pub-id pub-id-type="doi">10.1038/jcbfm.2008.8</pub-id>, PMID: <pub-id pub-id-type="pmid">18301432</pub-id>
</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De-Paula</surname><given-names>V. d. J. R.</given-names></name><name><surname>Forlenza</surname><given-names>A. S.</given-names></name><name><surname>Forlenza</surname><given-names>O. V.</given-names></name></person-group> (<year>2018</year>). <article-title>Relevance of gutmicrobiota in cognition, behaviour and Alzheimer's disease</article-title>. <source>Pharmacol. Res.</source>
<volume>136</volume>, <fpage>29</fpage>&#x02013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.phrs.2018.07.007</pub-id>, PMID: <pub-id pub-id-type="pmid">30138667</pub-id>
</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Cristo</surname><given-names>F.</given-names></name><name><surname>Finicelli</surname><given-names>M.</given-names></name><name><surname>Digilio</surname><given-names>F. A.</given-names></name><name><surname>Paladino</surname><given-names>S.</given-names></name><name><surname>Valentino</surname><given-names>A.</given-names></name><name><surname>Scialo</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Meldonium improves Huntington's disease mitochondrial dysfunction by restoring&#x0202f;peroxisome proliferator-activated receptor gamma coactivator 1alpha expression</article-title>. <source>J. Cell. Physiol.</source>
<volume>234</volume>, <fpage>9233</fpage>&#x02013;<lpage>9246</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcp.27602</pub-id><pub-id pub-id-type="pmid">30362565</pub-id>
</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doig</surname><given-names>A. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Positive feedback loops in Alzheimer's disease: the Alzheimer's feedback hypothesis</article-title>. <source>J. Alzheimers Dis.</source>
<volume>66</volume>, <fpage>25</fpage>&#x02013;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-180583</pub-id>, PMID: <pub-id pub-id-type="pmid">30282364</pub-id>
</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Emam</surname><given-names>M. A.</given-names></name><name><surname>Sheta</surname><given-names>E.</given-names></name><name><surname>El-Abhar</surname><given-names>H. S.</given-names></name><name><surname>Abdallah</surname><given-names>D. M.</given-names></name><name><surname>El</surname><given-names>K. A.</given-names></name><name><surname>Eldehna</surname><given-names>W. M.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Morin suppresses mTORc1/IRE-1alpha/JNK and IP3R-VDAC-1 pathways: crucial mechanisms&#x0202f;in apoptosis and mitophagy inhibition in experimental Huntington's disease, supported by in silico molecular docking simulations</article-title>. <source>Life Sci.</source>
<volume>338</volume>:<fpage>122362</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lfs.2023.122362</pub-id><pub-id pub-id-type="pmid">38141855</pub-id>
</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elesawy</surname><given-names>W. H.</given-names></name><name><surname>El-Sahar</surname><given-names>A. E.</given-names></name><name><surname>Sayed</surname><given-names>R. H.</given-names></name><name><surname>Ashour</surname><given-names>A. M.</given-names></name><name><surname>Alsufyani</surname><given-names>S. E.</given-names></name><name><surname>Arab</surname><given-names>H. H.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Repurposing ezetimibe as a neuroprotective agent in a rotenone-induced Parkinson's disease model in rats: role of AMPK/SIRT-1/PGC-1alpha signaling and autophagy</article-title>. <source>Int. Immunopharmacol.</source>
<volume>138</volume>:<fpage>112640</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.intimp.2024.112640</pub-id>, PMID: <pub-id pub-id-type="pmid">38981225</pub-id>
</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eschbach</surname><given-names>J.</given-names></name><name><surname>Schwalenstocker</surname><given-names>B.</given-names></name><name><surname>Soyal</surname><given-names>S. M.</given-names></name><name><surname>Bayer</surname><given-names>H.</given-names></name><name><surname>Wiesner</surname><given-names>D.</given-names></name><name><surname>Akimoto</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>PGC-1alpha is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis</article-title>. <source>Hum. Mol. Genet.</source>
<volume>22</volume>, <fpage>3477</fpage>&#x02013;<lpage>3484</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddt202</pub-id>, PMID: <pub-id pub-id-type="pmid">23669350</pub-id>
</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>S.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Shikonin blocks CAF-induced TNBC metastasis by suppressing mitochondrial biogenesis through GSK-3beta/NEDD4-1 mediated phosphorylation-dependent degradation of PGC-1alpha</article-title>. <source>J. Exp. Clin. Cancer Res.</source>
<volume>43</volume>:<fpage>180</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13046-024-03101-z</pub-id>, PMID: <pub-id pub-id-type="pmid">38937832</pub-id>
</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Mu</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Lian</surname><given-names>B.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>FGF21 protects dopaminergic neurons in Parkinson's disease models via repression of neuroinflammation</article-title>. <source>Neurotox. Res.</source>
<volume>37</volume>, <fpage>616</fpage>&#x02013;<lpage>627</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12640-019-00151-6</pub-id>, PMID: <pub-id pub-id-type="pmid">31997152</pub-id>
</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feigin</surname><given-names>V. L.</given-names></name><name><surname>Lawes</surname><given-names>C. M.</given-names></name><name><surname>Bennett</surname><given-names>D. A.</given-names></name><name><surname>Anderson</surname><given-names>C. S.</given-names></name></person-group> (<year>2003</year>). <article-title>Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century</article-title>. <source>Lancet Neurol.</source>
<volume>2</volume>, <fpage>43</fpage>&#x02013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s1474-4422(03)00266-7</pub-id>, PMID: <pub-id pub-id-type="pmid">12849300</pub-id>
</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira-Vieira</surname><given-names>T. H.</given-names></name><name><surname>Guimaraes</surname><given-names>I. M.</given-names></name><name><surname>Silva</surname><given-names>F. R.</given-names></name><name><surname>Ribeiro</surname><given-names>F. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Alzheimer's disease: targeting the cholinergic system</article-title>. <source>Curr. Neuropharmacol.</source>
<volume>14</volume>, <fpage>101</fpage>&#x02013;<lpage>115</lpage>. doi: <pub-id pub-id-type="doi">10.2174/1570159x13666150716165726</pub-id>, PMID: <pub-id pub-id-type="pmid">26813123</pub-id>
</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Anrather</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>F. D.</given-names></name></person-group> (<year>2015</year>). <article-title>Immune interventions in stroke</article-title>. <source>Nat. Rev. Neurol.</source>
<volume>11</volume>, <fpage>524</fpage>&#x02013;<lpage>535</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrneurol.2015.144</pub-id>, PMID: <pub-id pub-id-type="pmid">26303850</pub-id>
</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funayama</surname><given-names>M.</given-names></name><name><surname>Ohe</surname><given-names>K.</given-names></name><name><surname>Amo</surname><given-names>T.</given-names></name><name><surname>Furuya</surname><given-names>N.</given-names></name><name><surname>Yamaguchi</surname><given-names>J.</given-names></name><name><surname>Saiki</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study</article-title>. <source>Lancet Neurol.</source>
<volume>14</volume>, <fpage>274</fpage>&#x02013;<lpage>282</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(14)70266-2</pub-id>, PMID: <pub-id pub-id-type="pmid">25662902</pub-id>
</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giau</surname><given-names>V. V.</given-names></name><name><surname>Wu</surname><given-names>S. Y.</given-names></name><name><surname>Jamerlan</surname><given-names>A.</given-names></name><name><surname>An</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>S. Y.</given-names></name><name><surname>Hulme</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Gut microbiota and their Neuroinflammatory implications in Alzheimer's disease</article-title>. <source>Nutrients</source>
<volume>10</volume>:<fpage>765</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu10111765</pub-id>, PMID: <pub-id pub-id-type="pmid">29899304</pub-id>
</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golko-Perez</surname><given-names>S.</given-names></name><name><surname>Amit</surname><given-names>T.</given-names></name><name><surname>Bar-Am</surname><given-names>O.</given-names></name><name><surname>Youdim</surname><given-names>M. B.</given-names></name><name><surname>Weinreb</surname><given-names>O.</given-names></name></person-group> (<year>2017</year>). <article-title>A novel iron Chelator-radical scavenger ameliorates motor dysfunction and&#x0202f;improves life span and mitochondrial biogenesis in SOD1(G93A) ALS mice</article-title>. <source>Neurotox. Res.</source>
<volume>31</volume>, <fpage>230</fpage>&#x02013;<lpage>244</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12640-016-9677-6</pub-id><pub-id pub-id-type="pmid">27826939</pub-id>
</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunewald</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>K. R.</given-names></name><name><surname>Sue</surname><given-names>C. M.</given-names></name></person-group> (<year>2019</year>). <article-title>New insights into the complex role of mitochondria in Parkinson's disease</article-title>. <source>Prog. Neurobiol.</source>
<volume>177</volume>, <fpage>73</fpage>&#x02013;<lpage>93</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pneurobio.2018.09.003</pub-id>, PMID: <pub-id pub-id-type="pmid">30219247</pub-id>
</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Kai</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Cerebrolysin ameliorates focal cerebral ischemia injury through Neuroinflammatory&#x0202f;inhibition via CREB/PGC-1alpha pathway</article-title>. <source>Front. Pharmacol.</source>
<volume>10</volume>:<fpage>1245</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2019.01245</pub-id><pub-id pub-id-type="pmid">31695614</pub-id>
</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>B.</given-names></name><name><surname>Zheng</surname><given-names>C.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Luo</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Tetramethylpyrazine nitrone exerts neuroprotection via activation of PGC-1alpha/Nrf2 pathway in Parkinson's disease models</article-title>. <source>J. Adv. Res.</source>
<volume>64</volume>, <fpage>195</fpage>&#x02013;<lpage>211</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jare.2023.11.021</pub-id>, PMID: <pub-id pub-id-type="pmid">37989471</pub-id>
</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Cui</surname><given-names>P.</given-names></name><name><surname>Zheng</surname><given-names>K.</given-names></name><name><surname>Dang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Microglial PGC-1alpha protects against ischemic brain injury by suppressing neuroinflammation</article-title>. <source>Genome Med.</source>
<volume>13</volume>:<fpage>47</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13073-021-00863-5</pub-id>, PMID: <pub-id pub-id-type="pmid">33771213</pub-id>
</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y. S.</given-names></name><name><surname>Lee</surname><given-names>J. H.</given-names></name><name><surname>Lee</surname><given-names>S. H.</given-names></name></person-group> (<year>2019</year>). <article-title>Fucoidan suppresses mitochondrial dysfunction and cell death against&#x0202f;1-Methyl-4-Phenylpyridinum-induced neuronal cytotoxicity via regulation of PGC-1alpha&#x0202f;expression</article-title>. <source>Mar. Drugs</source>
<volume>17</volume>:<fpage>518</fpage>. doi: <pub-id pub-id-type="doi">10.3390/md17090518</pub-id><pub-id pub-id-type="pmid">31480724</pub-id>
</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J.</given-names></name><name><surname>Selkoe</surname><given-names>D. J.</given-names></name></person-group> (<year>2002</year>). <article-title>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</article-title>. <source>Science</source>
<volume>297</volume>, <fpage>353</fpage>&#x02013;<lpage>356</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1072994</pub-id>, PMID: <pub-id pub-id-type="pmid">12130773</pub-id>
</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Lang</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name></person-group> (<year>2015</year>). <article-title>The neuroprotective effect of Tetramethylpyrazine against contusive spinal cord injury by activating PGC-1alpha in rats</article-title>. <source>Neurochem. Res.</source>
<volume>40</volume>, <fpage>1393</fpage>&#x02013;<lpage>1401</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11064-015-1606-1</pub-id>, PMID: <pub-id pub-id-type="pmid">25981953</pub-id>
</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Lang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Ni</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>Lentivirus-mediated PGC-1alpha overexpression protects against traumatic spinal cord injury in rats</article-title>. <source>Neuroscience</source>
<volume>328</volume>, <fpage>40</fpage>&#x02013;<lpage>49</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.04.031</pub-id>, PMID: <pub-id pub-id-type="pmid">27132229</pub-id>
</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>TBN improves motor function and prolongs survival in a TDP-43M337V mouse model of&#x0202f;ALS</article-title>. <source>Hum. Mol. Genet.</source>
<volume>30</volume>, <fpage>1484</fpage>&#x02013;<lpage>1496</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddab101</pub-id><pub-id pub-id-type="pmid">33929499</pub-id>
</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>A. N.</given-names></name></person-group> (<year>2021</year>). <article-title>Glial cells promote myelin formation and elimination</article-title>. <source>Front. Cell Dev. Biol.</source>
<volume>9</volume>:<fpage>661486</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcell.2021.661486</pub-id>, PMID: <pub-id pub-id-type="pmid">34046407</pub-id>
</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Intihar</surname><given-names>T. A.</given-names></name><name><surname>Martinez</surname><given-names>E. A.</given-names></name><name><surname>Gomez-Pastor</surname><given-names>R.</given-names></name></person-group> (<year>2019</year>). <article-title>Mitochondrial dysfunction in Huntington's disease; interplay between HSF1, p53 and PGC-1alpha transcription factors</article-title>. <source>Front. Cell. Neurosci.</source>
<volume>13</volume>:<fpage>103</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2019.00103</pub-id>, PMID: <pub-id pub-id-type="pmid">30941017</pub-id>
</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankovic</surname><given-names>J.</given-names></name><name><surname>Tan</surname><given-names>E. K.</given-names></name></person-group> (<year>2020</year>). <article-title>Parkinson's disease: etiopathogenesis and treatment</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source>
<volume>91</volume>, <fpage>795</fpage>&#x02013;<lpage>808</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp-2019-322338</pub-id>, PMID: <pub-id pub-id-type="pmid">32576618</pub-id>
</mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>S. K.</given-names></name><name><surname>Michaels</surname><given-names>N. J.</given-names></name><name><surname>Ilyntskyy</surname><given-names>S.</given-names></name><name><surname>Keough</surname><given-names>M. B.</given-names></name><name><surname>Kovalchuk</surname><given-names>O.</given-names></name><name><surname>Yong</surname><given-names>V. W.</given-names></name></person-group> (<year>2018</year>). <article-title>Multimodal enhancement of Remyelination by exercise with a pivotal role for Oligodendroglial PGC1alpha</article-title>. <source>Cell Rep.</source>
<volume>24</volume>, <fpage>3167</fpage>&#x02013;<lpage>3179</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2018.08.060</pub-id>, PMID: <pub-id pub-id-type="pmid">30232000</pub-id>
</mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jesse</surname><given-names>S.</given-names></name><name><surname>Bayer</surname><given-names>H.</given-names></name><name><surname>Alupei</surname><given-names>M. C.</given-names></name><name><surname>Zugel</surname><given-names>M.</given-names></name><name><surname>Mulaw</surname><given-names>M.</given-names></name><name><surname>Tuorto</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Ribosomal transcription is regulated by PGC-1alpha and disturbed in Huntington's disease</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>:<fpage>8513</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-017-09148-7</pub-id>, PMID: <pub-id pub-id-type="pmid">28819135</pub-id>
</mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jessen</surname><given-names>K. R.</given-names></name></person-group> (<year>2004</year>). <article-title>Glial cells</article-title>. <source>Int. J. Biochem. Cell Biol.</source>
<volume>36</volume>, <fpage>1861</fpage>&#x02013;<lpage>1867</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biocel.2004.02.023</pub-id>, PMID: <pub-id pub-id-type="pmid">15203098</pub-id>
</mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jhuo</surname><given-names>C. F.</given-names></name><name><surname>Chen</surname><given-names>C. J.</given-names></name><name><surname>Tzen</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>W. Y.</given-names></name></person-group> (<year>2024</year>). <article-title>Teaghrelin protected dopaminergic neurons in MPTP-induced Parkinson's disease animal model by promoting PINK1/parkin-mediated mitophagy and AMPK/SIRT1/PGC1-alpha-mediated mitochondrial biogenesis</article-title>. <source>Environ. Toxicol.</source>
<volume>39</volume>, <fpage>4022</fpage>&#x02013;<lpage>4034</lpage>. doi: <pub-id pub-id-type="doi">10.1002/tox.24275</pub-id>, PMID: <pub-id pub-id-type="pmid">38622810</pub-id>
</mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Kang</surname><given-names>S. U.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Karuppagounder</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>Y. K.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Adult conditional knockout of PGC-1&#x003b1; leads to loss of dopamine neurons</article-title>. <source>eNeuro</source>
<volume>3</volume>:<fpage>ENEURO.0183</fpage>. doi: <pub-id pub-id-type="doi">10.1523/ENEURO.0183-16.2016</pub-id>, PMID: <pub-id pub-id-type="pmid">27622213</pub-id>
</mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez-Sanchez</surname><given-names>M.</given-names></name><name><surname>Licitra</surname><given-names>F.</given-names></name><name><surname>Underwood</surname><given-names>B. R.</given-names></name><name><surname>Rubinsztein</surname><given-names>D. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Huntington's disease: mechanisms of pathogenesis and therapeutic strategies</article-title>. <source>Cold Spring Harb. Perspect. Med.</source>
<volume>7</volume>:<fpage>a024240</fpage>. doi: <pub-id pub-id-type="doi">10.1101/cshperspect.a024240</pub-id>, PMID: <pub-id pub-id-type="pmid">27940602</pub-id>
</mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>P.</given-names></name><name><surname>Qi</surname><given-names>D.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Lenahan</surname><given-names>C.</given-names></name><name><surname>Deng</surname><given-names>S.</given-names></name><name><surname>Tao</surname><given-names>X.</given-names></name></person-group> (<year>2022</year>). <article-title>Activation of LRP6 with HLY78 attenuates oxidative stress and neuronal apoptosis via GSK3beta/Sirt1/PGC-1alpha pathway after ICH</article-title>. <source>Oxidative Med. Cell. Longev.</source>
<volume>2022</volume>:<fpage>7542468</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2022/7542468</pub-id>, PMID: <pub-id pub-id-type="pmid">35419167</pub-id>
</mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Kam</surname><given-names>T. I.</given-names></name><name><surname>Kang</surname><given-names>S. U.</given-names></name><name><surname>Neifert</surname><given-names>S.</given-names></name><name><surname>Karuppagounder</surname><given-names>S. S.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease</article-title>. <source>Sci. Transl. Med.</source>
<volume>13</volume>:<fpage>eaax8891</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.aax8891</pub-id><pub-id pub-id-type="pmid">34321320</pub-id>
</mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jornayvaz</surname><given-names>F. R.</given-names></name><name><surname>Shulman</surname><given-names>G. I.</given-names></name></person-group> (<year>2010</year>). <article-title>Regulation of mitochondrial biogenesis</article-title>. <source>Essays Biochem.</source>
<volume>47</volume>, <fpage>69</fpage>&#x02013;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.1042/bse0470069</pub-id>, PMID: <pub-id pub-id-type="pmid">20533901</pub-id>
</mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurcau</surname><given-names>A.</given-names></name><name><surname>Jurcau</surname><given-names>C. M.</given-names></name></person-group> (<year>2023</year>). <article-title>Mitochondria in Huntington's disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies</article-title>. <source>Neural Regen. Res.</source>
<volume>18</volume>, <fpage>1472</fpage>&#x02013;<lpage>1477</lpage>. doi: <pub-id pub-id-type="doi">10.4103/1673-5374.360289</pub-id>, PMID: <pub-id pub-id-type="pmid">36571344</pub-id>
</mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Barve</surname><given-names>K. H.</given-names></name><name><surname>Kumar</surname><given-names>M. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease</article-title>. <source>Curr. Neuropharmacol.</source>
<volume>18</volume>, <fpage>1106</fpage>&#x02013;<lpage>1125</lpage>. doi: <pub-id pub-id-type="doi">10.2174/1570159X18666200528142429</pub-id>, PMID: <pub-id pub-id-type="pmid">32484110</pub-id>
</mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Xue</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis</article-title>. <source>PLoS One</source>
<volume>5</volume>:<fpage>e11707</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0011707</pub-id>, PMID: <pub-id pub-id-type="pmid">20661474</pub-id>
</mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Ratan</surname><given-names>R. R.</given-names></name></person-group> (<year>2016</year>). <article-title>Oxidative stress and Huntington's disease: the good, the bad, and the ugly</article-title>. <source>J. Huntingtons Dis.</source>
<volume>5</volume>, <fpage>217</fpage>&#x02013;<lpage>237</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JHD-160205</pub-id>, PMID: <pub-id pub-id-type="pmid">27662334</pub-id>
</mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Spada</surname><given-names>A. R.</given-names></name></person-group> (<year>2012</year>). <article-title>PPARGC1A/PGC-1alpha, TFEB and enhanced proteostasis in Huntington disease: defining regulatory linkages between energy production and protein-organelle quality control</article-title>. <source>Autophagy</source>
<volume>8</volume>, <fpage>1845</fpage>&#x02013;<lpage>1847</lpage>. doi: <pub-id pub-id-type="doi">10.4161/auto.21862</pub-id>, PMID: <pub-id pub-id-type="pmid">22932698</pub-id>
</mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langston</surname><given-names>J. W.</given-names></name><name><surname>Ballard</surname><given-names>P. J.</given-names></name></person-group> (<year>1983</year>). <article-title>Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine</article-title>. <source>N. Engl. J. Med.</source>
<volume>309</volume>:<fpage>310</fpage>. doi: <pub-id pub-id-type="doi">10.1056/nejm198308043090511</pub-id>, PMID: <pub-id pub-id-type="pmid">6602944</pub-id>
</mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapchak</surname><given-names>P. A.</given-names></name><name><surname>Zhang</surname><given-names>J. H.</given-names></name></person-group> (<year>2017</year>). <article-title>The high cost of stroke and stroke Cytoprotection research</article-title>. <source>Transl. Stroke Res.</source>
<volume>8</volume>, <fpage>307</fpage>&#x02013;<lpage>317</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12975-016-0518-y</pub-id>, PMID: <pub-id pub-id-type="pmid">28039575</pub-id>
</mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leavitt</surname><given-names>B. R.</given-names></name><name><surname>Kordasiewicz</surname><given-names>H. B.</given-names></name><name><surname>Schobel</surname><given-names>S. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Huntingtin-lowering therapies for Huntington disease: A review of the evidence of potential benefits and risks</article-title>. <source>JAMA Neurol.</source>
<volume>77</volume>, <fpage>764</fpage>&#x02013;<lpage>772</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2020.0299</pub-id>, PMID: <pub-id pub-id-type="pmid">32202594</pub-id>
</mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>T. K.</given-names></name><name><surname>Ashok</surname><given-names>K. K.</given-names></name><name><surname>Huang</surname><given-names>C. Y.</given-names></name><name><surname>Liao</surname><given-names>P. H.</given-names></name><name><surname>Ho</surname><given-names>T. J.</given-names></name><name><surname>Kuo</surname><given-names>W. W.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Garcinol protects SH-SY5Y cells against MPP+-induced cell death by activating DJ-1/SIRT1 and PGC-1alpha mediated antioxidant pathway in sequential stimulation of p-AMPK mediated autophagy</article-title>. <source>Environ. Toxicol.</source>
<volume>38</volume>, <fpage>857</fpage>&#x02013;<lpage>866</lpage>. doi: <pub-id pub-id-type="doi">10.1002/tox.23737</pub-id>, PMID: <pub-id pub-id-type="pmid">36629037</pub-id>
</mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Ban</surname><given-names>J. J.</given-names></name><name><surname>Chung</surname><given-names>J. Y.</given-names></name><name><surname>Im</surname><given-names>W.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Amelioration of Huntington's disease phenotypes by Beta-Lapachone is associated&#x0202f;with increases in Sirt1 expression, CREB phosphorylation and PGC-1alpha&#x0202f;deacetylation</article-title>. <source>PLoS One</source>
<volume>13</volume>:<fpage>e0195968</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0195968</pub-id><pub-id pub-id-type="pmid">29742127</pub-id>
</mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Ban</surname><given-names>J. J.</given-names></name><name><surname>Won</surname><given-names>B. H.</given-names></name><name><surname>Im</surname><given-names>W.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Therapeutic potential of ginsenoside Rg3 and Rf for Huntington's disease</article-title>. <source>In vitro cell Dev. Biol.-Anim.</source>
<volume>57</volume>, <fpage>641</fpage>&#x02013;<lpage>648</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11626-021-00595-1</pub-id><pub-id pub-id-type="pmid">34128157</pub-id>
</mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Martins</surname><given-names>S.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Hou</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Is the high frequency of Machado-Joseph disease in China due to new mutational origins?</article-title>
<source>Front. Genet.</source>
<volume>9</volume>:<fpage>740</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fgene.2018.00740</pub-id>, PMID: <pub-id pub-id-type="pmid">30842792</pub-id>
</mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Miro1 regulates neuronal mitochondrial transport and distribution to alleviate neuronal damage in secondary brain injury after intracerebral Hemorrhage in rats</article-title>. <source>Cell. Mol. Neurobiol.</source>
<volume>41</volume>, <fpage>795</fpage>&#x02013;<lpage>812</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10571-020-00887-2</pub-id>, PMID: <pub-id pub-id-type="pmid">32500352</pub-id>
</mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>H.</given-names></name><name><surname>Ward</surname><given-names>W. F.</given-names></name><name><surname>Jang</surname><given-names>Y. C.</given-names></name><name><surname>Bhattacharya</surname><given-names>A.</given-names></name><name><surname>Bokov</surname><given-names>A. F.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>PGC-1alpha protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model</article-title>. <source>Muscle Nerve</source>
<volume>44</volume>, <fpage>947</fpage>&#x02013;<lpage>956</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mus.22217</pub-id>, PMID: <pub-id pub-id-type="pmid">22102466</pub-id>
</mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Puigserver</surname><given-names>P.</given-names></name><name><surname>Donovan</surname><given-names>J.</given-names></name><name><surname>Tarr</surname><given-names>P.</given-names></name><name><surname>Spiegelman</surname><given-names>B. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC-1beta), a novel PGC-1-related transcription coactivator associated with host cell factor</article-title>. <source>J. Biol. Chem.</source>
<volume>277</volume>, <fpage>1645</fpage>&#x02013;<lpage>1648</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.C100631200</pub-id>, PMID: <pub-id pub-id-type="pmid">11733490</pub-id>
</mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>P. H.</given-names></name><name><surname>Tarr</surname><given-names>P. T.</given-names></name><name><surname>Lindenberg</surname><given-names>K. S.</given-names></name><name><surname>St-Pierre</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>C. Y.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice</article-title>. <source>Cell</source>
<volume>119</volume>, <fpage>121</fpage>&#x02013;<lpage>135</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2004.09.013</pub-id>, PMID: <pub-id pub-id-type="pmid">15454086</pub-id>
</mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Qiu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhuo</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Urolithin A protects dopaminergic neurons in experimental models of Parkinson's disease by promoting mitochondrial biogenesis through the SIRT1/PGC-1alpha signaling pathway</article-title>. <source>Food Funct.</source>
<volume>13</volume>, <fpage>375</fpage>&#x02013;<lpage>385</lpage>. doi: <pub-id pub-id-type="doi">10.1039/d1fo02534a</pub-id>, PMID: <pub-id pub-id-type="pmid">34905594</pub-id>
</mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Lyu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name></person-group> (<year>2023</year>). <article-title>Astaxanthin attenuates cognitive deficits in Alzheimer's disease models by reducing oxidative stress via the SIRT1/PGC-1alpha signaling pathway</article-title>. <source>Cell Biosci.</source>
<volume>13</volume>:<fpage>173</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13578-023-01129-w</pub-id>, PMID: <pub-id pub-id-type="pmid">37710272</pub-id>
</mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S. G.</given-names></name><name><surname>Wang</surname><given-names>Y. M.</given-names></name><name><surname>Zhang</surname><given-names>Y. J.</given-names></name><name><surname>He</surname><given-names>X. J.</given-names></name><name><surname>Ma</surname><given-names>T.</given-names></name><name><surname>Song</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>ZL006 protects spinal cord neurons against ischemia-induced oxidative stress through AMPK-PGC-1alpha-Sirt3 pathway</article-title>. <source>Neurochem. Int.</source>
<volume>108</volume>, <fpage>230</fpage>&#x02013;<lpage>237</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuint.2017.04.005</pub-id>, PMID: <pub-id pub-id-type="pmid">28411102</pub-id>
</mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>E. K.</given-names></name><name><surname>Dougherty</surname><given-names>S. E.</given-names></name><name><surname>McMeekin</surname><given-names>L. J.</given-names></name><name><surname>Reid</surname><given-names>C. S.</given-names></name><name><surname>Dobrunz</surname><given-names>L. E.</given-names></name><name><surname>West</surname><given-names>A. B.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>PGC-1alpha provides a transcriptional framework for synchronous neurotransmitter release from parvalbumin-positive interneurons</article-title>. <source>J. Neurosci.</source>
<volume>34</volume>, <fpage>14375</fpage>&#x02013;<lpage>14387</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1222-14.2014</pub-id>, PMID: <pub-id pub-id-type="pmid">25339750</pub-id>
</mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>E. K.</given-names></name><name><surname>Markwardt</surname><given-names>S. J.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Meador-Woodruff</surname><given-names>J. H.</given-names></name><name><surname>Lin</surname><given-names>J. D.</given-names></name><name><surname>Overstreet-Wadiche</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Parvalbumin deficiency and GABAergic dysfunction in mice lacking PGC-1alpha</article-title>. <source>J. Neurosci.</source>
<volume>30</volume>, <fpage>7227</fpage>&#x02013;<lpage>7235</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0698-10.2010</pub-id>, PMID: <pub-id pub-id-type="pmid">20505089</pub-id>
</mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>P. E.</given-names></name><name><surname>Das</surname><given-names>J. M.</given-names></name></person-group> (<year>2022</year>). <source>Histology, Glial Cells</source>. <publisher-loc>Treasure Island, FL</publisher-loc>: <publisher-name>StatPearls</publisher-name>.</mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Xin</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Forkhead box O proteins: crucial regulators of cancer EMT</article-title>. <source>Semin. Cancer Biol.</source>
<volume>50</volume>, <fpage>21</fpage>&#x02013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.semcancer.2018.02.004</pub-id>, PMID: <pub-id pub-id-type="pmid">29427645</pub-id>
</mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madani</surname><given-names>N. A.</given-names></name><name><surname>Nasseri</surname><given-names>M. S.</given-names></name><name><surname>Saberi</surname><given-names>P. M.</given-names></name><name><surname>Golmohammadi</surname><given-names>S.</given-names></name><name><surname>Nazarinia</surname><given-names>D.</given-names></name><name><surname>Aboutaleb</surname><given-names>N.</given-names></name></person-group> (<year>2021</year>). <article-title>Donepezil attenuates injury following ischaemic stroke by stimulation of&#x0202f;neurogenesis, angiogenesis, and inhibition of inflammation and apoptosis</article-title>. <source>Inflammopharmacology</source>
<volume>29</volume>, <fpage>153</fpage>&#x02013;<lpage>166</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10787-020-00769-5</pub-id><pub-id pub-id-type="pmid">33201349</pub-id>
</mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makela</surname><given-names>J.</given-names></name><name><surname>Tselykh</surname><given-names>T. V.</given-names></name><name><surname>Maiorana</surname><given-names>F.</given-names></name><name><surname>Eriksson</surname><given-names>O.</given-names></name><name><surname>Do</surname><given-names>H. T.</given-names></name><name><surname>Mudo</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1alpha in human dopaminergic neurons via Sirtuin-1</article-title>. <source>Springerplus</source>
<volume>3</volume>:<fpage>2</fpage>. doi: <pub-id pub-id-type="doi">10.1186/2193-1801-3-2</pub-id>, PMID: <pub-id pub-id-type="pmid">25932355</pub-id>
</mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattiasson</surname><given-names>G.</given-names></name><name><surname>Shamloo</surname><given-names>M.</given-names></name><name><surname>Gido</surname><given-names>G.</given-names></name><name><surname>Mathi</surname><given-names>K.</given-names></name><name><surname>Tomasevic</surname><given-names>G.</given-names></name><name><surname>Yi</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma</article-title>. <source>Nat. Med.</source>
<volume>9</volume>, <fpage>1062</fpage>&#x02013;<lpage>1068</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nm903</pub-id>, PMID: <pub-id pub-id-type="pmid">12858170</pub-id>
</mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMeekin</surname><given-names>L. J.</given-names></name><name><surname>Bartley</surname><given-names>A. F.</given-names></name><name><surname>Bohannon</surname><given-names>A. S.</given-names></name><name><surname>Adlaf</surname><given-names>E. W.</given-names></name><name><surname>van Groen</surname><given-names>T.</given-names></name><name><surname>Boas</surname><given-names>S. M.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>A role for PGC-1alpha in transcription and excitability of neocortical and hippocampal excitatory neurons</article-title>. <source>Neuroscience</source>
<volume>435</volume>, <fpage>73</fpage>&#x02013;<lpage>94</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroscience.2020.03.036</pub-id>, PMID: <pub-id pub-id-type="pmid">32222555</pub-id>
</mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meara</surname><given-names>R. J.</given-names></name></person-group> (<year>1994</year>). <article-title>Review: the pathophysiology of the motor signs in Parkinson's disease</article-title>. <source>Age Ageing</source>
<volume>23</volume>, <fpage>342</fpage>&#x02013;<lpage>346</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ageing/23.4.342</pub-id>, PMID: <pub-id pub-id-type="pmid">7976786</pub-id>
</mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>A. R.</given-names></name><name><surname>Gregory</surname><given-names>J. M.</given-names></name><name><surname>Dando</surname><given-names>O.</given-names></name><name><surname>Carter</surname><given-names>R. N.</given-names></name><name><surname>Burr</surname><given-names>K.</given-names></name><name><surname>Nanda</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis</article-title>. <source>Acta Neuropathol.</source>
<volume>141</volume>, <fpage>257</fpage>&#x02013;<lpage>279</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00401-020-02252-5</pub-id>, PMID: <pub-id pub-id-type="pmid">33398403</pub-id>
</mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name></person-group> (<year>2024</year>). <article-title>Extending dual-targeting upper-limit in liposomal delivery of lithospermic acid B for Alzheimer's mitochondrial revitalization</article-title>. <source>J. Control. Release</source>
<volume>367</volume>, <fpage>604</fpage>&#x02013;<lpage>619</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jconrel.2024.01.059</pub-id>, PMID: <pub-id pub-id-type="pmid">38295997</pub-id>
</mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammed</surname><given-names>N. N.</given-names></name><name><surname>Tadros</surname><given-names>M. G.</given-names></name><name><surname>George</surname><given-names>M. Y.</given-names></name></person-group> (<year>2024</year>). <article-title>Empagliflozin repurposing in Parkinson's disease; modulation of oxidative stress, neuroinflammation, AMPK/SIRT-1/PGC-1alpha, and wnt/beta-catenin pathways</article-title>. <source>Inflammopharmacology</source>
<volume>32</volume>, <fpage>777</fpage>&#x02013;<lpage>794</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10787-023-01384-w</pub-id>, PMID: <pub-id pub-id-type="pmid">38038781</pub-id>
</mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monsalve</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Adelmant</surname><given-names>G.</given-names></name><name><surname>Puigserver</surname><given-names>P.</given-names></name><name><surname>Fan</surname><given-names>M.</given-names></name><name><surname>Spiegelman</surname><given-names>B. M.</given-names></name></person-group> (<year>2000</year>). <article-title>Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1</article-title>. <source>Mol. Cell</source>
<volume>6</volume>, <fpage>307</fpage>&#x02013;<lpage>316</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s1097-2765(00)00031-9</pub-id>, PMID: <pub-id pub-id-type="pmid">10983978</pub-id>
</mixed-citation></ref><ref id="ref93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naia</surname><given-names>L.</given-names></name><name><surname>Rosenstock</surname><given-names>T. R.</given-names></name><name><surname>Oliveira</surname><given-names>A. M.</given-names></name><name><surname>Oliveira-Sousa</surname><given-names>S. I.</given-names></name><name><surname>Caldeira</surname><given-names>G. L.</given-names></name><name><surname>Carmo</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Comparative mitochondrial-based protective effects of resveratrol and&#x0202f;nicotinamide in Huntington's disease models</article-title>. <source>Mol. Neurobiol.</source>
<volume>54</volume>, <fpage>5385</fpage>&#x02013;<lpage>5399</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-016-0048-3</pub-id><pub-id pub-id-type="pmid">27590140</pub-id>
</mixed-citation></ref><ref id="ref94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>H. P.</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C.</given-names></name><name><surname>van der Zee</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>ALS genes in the genomic era and their implications for FTD</article-title>. <source>Trends Genet.</source>
<volume>34</volume>, <fpage>404</fpage>&#x02013;<lpage>423</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tig.2018.03.001</pub-id>, PMID: <pub-id pub-id-type="pmid">29605155</pub-id>
</mixed-citation></ref><ref id="ref95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunnari</surname><given-names>J.</given-names></name><name><surname>Suomalainen</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Mitochondria: in sickness and in health</article-title>. <source>Cell</source>
<volume>148</volume>, <fpage>1145</fpage>&#x02013;<lpage>1159</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2012.02.035</pub-id>, PMID: <pub-id pub-id-type="pmid">22424226</pub-id>
</mixed-citation></ref><ref id="ref96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>L. C.</given-names></name><name><surname>Keeney</surname><given-names>P. M.</given-names></name><name><surname>Bennett</surname><given-names>J. J.</given-names></name></person-group> (<year>2015</year>). <article-title>Differentiation of human neural stem cells into motor neurons stimulates mitochondrial biogenesis and decreases glycolytic flux</article-title>. <source>Stem Cells Dev.</source>
<volume>24</volume>, <fpage>1984</fpage>&#x02013;<lpage>1994</lpage>. doi: <pub-id pub-id-type="doi">10.1089/scd.2015.0076</pub-id>, PMID: <pub-id pub-id-type="pmid">25892363</pub-id>
</mixed-citation></ref><ref id="ref97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paisan-Ruiz</surname><given-names>C.</given-names></name><name><surname>Jain</surname><given-names>S.</given-names></name><name><surname>Evans</surname><given-names>E. W.</given-names></name><name><surname>Gilks</surname><given-names>W. P.</given-names></name><name><surname>Simon</surname><given-names>J.</given-names></name><name><surname>van der Brug</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease</article-title>. <source>Neuron</source>
<volume>44</volume>, <fpage>595</fpage>&#x02013;<lpage>600</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuron.2004.10.023</pub-id>, PMID: <pub-id pub-id-type="pmid">15541308</pub-id>
</mixed-citation></ref><ref id="ref98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panes</surname><given-names>J. D.</given-names></name><name><surname>Godoy</surname><given-names>P. A.</given-names></name><name><surname>Silva-Grecchi</surname><given-names>T.</given-names></name><name><surname>Celis</surname><given-names>M. T.</given-names></name><name><surname>Ramirez-Molina</surname><given-names>O.</given-names></name><name><surname>Gavilan</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Changes in PGC-1alpha/SIRT1 Signaling impact on mitochondrial homeostasis in amyloid-Beta peptide toxicity model</article-title>. <source>Front. Pharmacol.</source>
<volume>11</volume>:<fpage>709</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2020.00709</pub-id>, PMID: <pub-id pub-id-type="pmid">32523530</pub-id>
</mixed-citation></ref><ref id="ref99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pohland</surname><given-names>M.</given-names></name><name><surname>Pellowska</surname><given-names>M.</given-names></name><name><surname>Asseburg</surname><given-names>H.</given-names></name><name><surname>Hagl</surname><given-names>S.</given-names></name><name><surname>Reutzel</surname><given-names>M.</given-names></name><name><surname>Joppe</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer's disease</article-title>. <source>Alzheimers Res. Ther.</source>
<volume>10</volume>:<fpage>18</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13195-018-0342-6</pub-id>, PMID: <pub-id pub-id-type="pmid">29433569</pub-id>
</mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polymeropoulos</surname><given-names>M. H.</given-names></name><name><surname>Lavedan</surname><given-names>C.</given-names></name><name><surname>Leroy</surname><given-names>E.</given-names></name><name><surname>Ide</surname><given-names>S. E.</given-names></name><name><surname>Dehejia</surname><given-names>A.</given-names></name><name><surname>Dutra</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>1997</year>). <article-title>Mutation in the alpha-synuclein gene identified in families with Parkinson's disease</article-title>. <source>Science</source>
<volume>276</volume>, <fpage>2045</fpage>&#x02013;<lpage>2047</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.276.5321.2045</pub-id>, PMID: <pub-id pub-id-type="pmid">9197268</pub-id>
</mixed-citation></ref><ref id="ref101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>N. L.</given-names></name><name><surname>Gomes</surname><given-names>A. P.</given-names></name><name><surname>Ling</surname><given-names>A. J.</given-names></name><name><surname>Duarte</surname><given-names>F. V.</given-names></name><name><surname>Martin-Montalvo</surname><given-names>A.</given-names></name><name><surname>North</surname><given-names>B. J.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function</article-title>. <source>Cell Metab.</source>
<volume>15</volume>, <fpage>675</fpage>&#x02013;<lpage>690</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2012.04.003</pub-id>, PMID: <pub-id pub-id-type="pmid">22560220</pub-id>
</mixed-citation></ref><ref id="ref102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>A.</given-names></name><name><surname>Grosgen</surname><given-names>S.</given-names></name><name><surname>Mett</surname><given-names>J.</given-names></name><name><surname>Zimmer</surname><given-names>V. C.</given-names></name><name><surname>Haupenthal</surname><given-names>V. J.</given-names></name><name><surname>Hundsdorfer</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Upregulation of PGC-1alpha expression by Alzheimer's disease-associated pathway: presenilin 1/amyloid precursor protein (APP)/intracellular domain of APP</article-title>. <source>Aging Cell</source>
<volume>13</volume>, <fpage>263</fpage>&#x02013;<lpage>272</lpage>. doi: <pub-id pub-id-type="doi">10.1111/acel.12183</pub-id>, PMID: <pub-id pub-id-type="pmid">24304563</pub-id>
</mixed-citation></ref><ref id="ref103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosin</surname><given-names>J. M.</given-names></name><name><surname>McAllister</surname><given-names>B. B.</given-names></name><name><surname>Dyck</surname><given-names>R. H.</given-names></name><name><surname>Percival</surname><given-names>C. J.</given-names></name><name><surname>Kurrasch</surname><given-names>D. M.</given-names></name><name><surname>Cobb</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Mice lacking the transcription factor SHOX2 display impaired cerebellar development and deficits in motor coordination</article-title>. <source>Dev. Biol.</source>
<volume>399</volume>, <fpage>54</fpage>&#x02013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ydbio.2014.12.013</pub-id>, PMID: <pub-id pub-id-type="pmid">25528224</pub-id>
</mixed-citation></ref><ref id="ref104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>M.</given-names></name><name><surname>Heverin</surname><given-names>M.</given-names></name><name><surname>McLaughlin</surname><given-names>R. L.</given-names></name><name><surname>Hardiman</surname><given-names>O.</given-names></name></person-group> (<year>2019</year>). <article-title>Lifetime risk and heritability of amyotrophic lateral sclerosis</article-title>. <source>JAMA Neurol.</source>
<volume>76</volume>, <fpage>1367</fpage>&#x02013;<lpage>1374</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2019.2044</pub-id>, PMID: <pub-id pub-id-type="pmid">31329211</pub-id>
</mixed-citation></ref><ref id="ref105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schapira</surname><given-names>A. H.</given-names></name><name><surname>Cooper</surname><given-names>J. M.</given-names></name><name><surname>Dexter</surname><given-names>D.</given-names></name><name><surname>Jenner</surname><given-names>P.</given-names></name><name><surname>Clark</surname><given-names>J. B.</given-names></name><name><surname>Marsden</surname><given-names>C. D.</given-names></name></person-group> (<year>1989</year>). <article-title>Mitochondrial complex I deficiency in Parkinson's disease</article-title>. <source>Lancet</source>
<volume>333</volume>:<fpage>1269</fpage>. doi: <pub-id pub-id-type="doi">10.1016/s0140-6736(89)92366-0</pub-id>, PMID: <pub-id pub-id-type="pmid">2566813</pub-id>
</mixed-citation></ref><ref id="ref106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvakumar</surname><given-names>G. P.</given-names></name><name><surname>Iyer</surname><given-names>S. S.</given-names></name><name><surname>Kempuraj</surname><given-names>D.</given-names></name><name><surname>Raju</surname><given-names>M.</given-names></name><name><surname>Thangavel</surname><given-names>R.</given-names></name><name><surname>Saeed</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Glia maturation factor dependent inhibition of mitochondrial PGC-1alpha triggers oxidative stress-mediated apoptosis in N27 rat dopaminergic neuronal cells</article-title>. <source>Mol. Neurobiol.</source>
<volume>55</volume>, <fpage>7132</fpage>&#x02013;<lpage>7152</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-018-0882-6</pub-id>, PMID: <pub-id pub-id-type="pmid">29383690</pub-id>
</mixed-citation></ref><ref id="ref107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>B. N.</given-names></name><name><surname>Newhouse</surname><given-names>S.</given-names></name><name><surname>Shatunov</surname><given-names>A.</given-names></name><name><surname>Vance</surname><given-names>C.</given-names></name><name><surname>Topp</surname><given-names>S.</given-names></name><name><surname>Johnson</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder</article-title>. <source>Eur. J. Hum. Genet.</source>
<volume>21</volume>, <fpage>102</fpage>&#x02013;<lpage>108</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ejhg.2012.98</pub-id>, PMID: <pub-id pub-id-type="pmid">22692064</pub-id>
</mixed-citation></ref><ref id="ref108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>M.</given-names></name><name><surname>Yi</surname><given-names>F.</given-names></name><name><surname>Zeng</surname><given-names>F.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>USP18 stabilized FTO protein to activate Mitophagy in ischemic stroke through repressing m6A modification of SIRT6</article-title>. <source>Mol. Neurobiol.</source>
<volume>61</volume>, <fpage>6658</fpage>&#x02013;<lpage>6674</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-024-04001-1</pub-id>, PMID: <pub-id pub-id-type="pmid">38340205</pub-id>
</mixed-citation></ref><ref id="ref109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St-Pierre</surname><given-names>J.</given-names></name><name><surname>Drori</surname><given-names>S.</given-names></name><name><surname>Uldry</surname><given-names>M.</given-names></name><name><surname>Silvaggi</surname><given-names>J. M.</given-names></name><name><surname>Rhee</surname><given-names>J.</given-names></name><name><surname>Jager</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators</article-title>. <source>Cell</source>
<volume>127</volume>, <fpage>397</fpage>&#x02013;<lpage>408</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2006.09.024</pub-id>, PMID: <pub-id pub-id-type="pmid">17055439</pub-id>
</mixed-citation></ref><ref id="ref110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Naoxinqing tablet protects against cerebral ischemic/reperfusion injury by&#x0202f;regulating ampkalpha/NAMPT/SIRT1/PGC-1alpha pathway</article-title>. <source>J. Ethnopharmacol.</source>
<volume>322</volume>:<fpage>117672</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jep.2023.117672</pub-id><pub-id pub-id-type="pmid">38159826</pub-id>
</mixed-citation></ref><ref id="ref112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swanson</surname><given-names>C. R.</given-names></name><name><surname>Du</surname><given-names>E.</given-names></name><name><surname>Johnson</surname><given-names>D. A.</given-names></name><name><surname>Johnson</surname><given-names>J. A.</given-names></name><name><surname>Emborg</surname><given-names>M. E.</given-names></name></person-group> (<year>2013</year>). <article-title>Neuroprotective properties of a novel non-Thiazoledinedione partial PPAR- gamma agonist against MPTP</article-title>. <source>PPAR Res.</source>
<volume>2013</volume>:<fpage>582809</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2013/582809</pub-id>, PMID: <pub-id pub-id-type="pmid">24223584</pub-id>
</mixed-citation></ref><ref id="ref113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabrizi</surname><given-names>S. J.</given-names></name><name><surname>Ghosh</surname><given-names>R.</given-names></name><name><surname>Leavitt</surname><given-names>B. R.</given-names></name></person-group> (<year>2019</year>). <article-title>Huntingtin lowering strategies for disease modification in Huntington's disease</article-title>. <source>Neuron</source>
<volume>101</volume>, <fpage>801</fpage>&#x02013;<lpage>819</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuron.2019.01.039</pub-id>, PMID: <pub-id pub-id-type="pmid">30844400</pub-id>
</mixed-citation></ref><ref id="ref114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>F. L.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>J. X.</given-names></name><name><surname>Erion</surname><given-names>J. R.</given-names></name><name><surname>Ye</surname><given-names>J.</given-names></name><name><surname>Mei</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function</article-title>. <source>Cell Rep.</source>
<volume>12</volume>, <fpage>1631</fpage>&#x02013;<lpage>1643</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2015.08.001</pub-id>, PMID: <pub-id pub-id-type="pmid">26321632</pub-id>
</mixed-citation></ref><ref id="ref115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thau</surname><given-names>N.</given-names></name><name><surname>Knippenberg</surname><given-names>S.</given-names></name><name><surname>Korner</surname><given-names>S.</given-names></name><name><surname>Rath</surname><given-names>K. J.</given-names></name><name><surname>Dengler</surname><given-names>R.</given-names></name><name><surname>Petri</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Decreased mRNA expression of PGC-1alpha and PGC-1alpha-regulated factors in the SOD1G93A ALS mouse model and in human sporadic ALS</article-title>. <source>J. Neuropathol. Exp. Neurol.</source>
<volume>71</volume>, <fpage>1064</fpage>&#x02013;<lpage>1074</lpage>. doi: <pub-id pub-id-type="doi">10.1097/NEN.0b013e318275df4b</pub-id>, PMID: <pub-id pub-id-type="pmid">23147503</pub-id>
</mixed-citation></ref><ref id="ref116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>L.</given-names></name><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Yue</surname><given-names>R.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Qin</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Pretreatment with Tilianin improves mitochondrial energy metabolism and oxidative stress in rats with myocardial ischemia/reperfusion injury via AMPK/SIRT1/PGC-1 alpha signaling pathway</article-title>. <source>J. Pharmacol. Sci.</source>
<volume>139</volume>, <fpage>352</fpage>&#x02013;<lpage>360</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jphs.2019.02.008</pub-id>, PMID: <pub-id pub-id-type="pmid">30910451</pub-id>
</mixed-citation></ref><ref id="ref117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tritos</surname><given-names>N. A.</given-names></name><name><surname>Mastaitis</surname><given-names>J. W.</given-names></name><name><surname>Kokkotou</surname><given-names>E. G.</given-names></name><name><surname>Puigserver</surname><given-names>P.</given-names></name><name><surname>Spiegelman</surname><given-names>B. M.</given-names></name><name><surname>Maratos-Flier</surname><given-names>E.</given-names></name></person-group> (<year>2003</year>). <article-title>Characterization of the peroxisome proliferator activated receptor coactivator 1 alpha (PGC 1alpha) expression in the murine brain</article-title>. <source>Brain Res.</source>
<volume>961</volume>, <fpage>255</fpage>&#x02013;<lpage>260</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0006-8993(02)03961-6</pub-id>, PMID: <pub-id pub-id-type="pmid">12531492</pub-id>
</mixed-citation></ref><ref id="ref118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsunemi</surname><given-names>T.</given-names></name><name><surname>Ashe</surname><given-names>T. D.</given-names></name><name><surname>Morrison</surname><given-names>B. E.</given-names></name><name><surname>Soriano</surname><given-names>K. R.</given-names></name><name><surname>Au</surname><given-names>J.</given-names></name><name><surname>Roque</surname><given-names>R. A.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>PGC-1alpha rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function</article-title>. <source>Sci. Transl. Med.</source>
<volume>4</volume>:<fpage>142ra97</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.3003799</pub-id>, PMID: <pub-id pub-id-type="pmid">22786682</pub-id>
</mixed-citation></ref><ref id="ref119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tungtur</surname><given-names>S. K.</given-names></name><name><surname>Wilkins</surname><given-names>H. M.</given-names></name><name><surname>Rogers</surname><given-names>R. S.</given-names></name><name><surname>Badawi</surname><given-names>Y.</given-names></name><name><surname>Sage</surname><given-names>J. M.</given-names></name><name><surname>Agbas</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Oxaloacetate treatment preserves motor function in SOD1(G93A) mice and normalizes&#x0202f;select neuroinflammation-related parameters in the spinal cord</article-title>. <source>Sci. Rep.</source>
<volume>11</volume>:<fpage>11051</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-021-90438-6</pub-id><pub-id pub-id-type="pmid">34040085</pub-id>
</mixed-citation></ref><ref id="ref120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valerio</surname><given-names>A.</given-names></name><name><surname>Bertolotti</surname><given-names>P.</given-names></name><name><surname>Delbarba</surname><given-names>A.</given-names></name><name><surname>Perego</surname><given-names>C.</given-names></name><name><surname>Dossena</surname><given-names>M.</given-names></name><name><surname>Ragni</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production</article-title>. <source>J. Neurochem.</source>
<volume>116</volume>, <fpage>1148</fpage>&#x02013;<lpage>1159</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07171.x</pub-id>, PMID: <pub-id pub-id-type="pmid">21210815</pub-id>
</mixed-citation></ref><ref id="ref121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Asch</surname><given-names>C. J.</given-names></name><name><surname>Luitse</surname><given-names>M. J.</given-names></name><name><surname>Rinkel</surname><given-names>G. J.</given-names></name><name><surname>van der Tweel</surname><given-names>I.</given-names></name><name><surname>Algra</surname><given-names>A.</given-names></name><name><surname>Klijn</surname><given-names>C. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis</article-title>. <source>Lancet Neurol.</source>
<volume>9</volume>, <fpage>167</fpage>&#x02013;<lpage>176</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(09)70340-0</pub-id>, PMID: <pub-id pub-id-type="pmid">20056489</pub-id>
</mixed-citation></ref><ref id="ref122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Well</surname><given-names>E. M.</given-names></name><name><surname>Bader</surname><given-names>V.</given-names></name><name><surname>Patra</surname><given-names>M.</given-names></name><name><surname>Sanchez-Vicente</surname><given-names>A.</given-names></name><name><surname>Meschede</surname><given-names>J.</given-names></name><name><surname>Furthmann</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>A protein quality control pathway regulated by linear ubiquitination</article-title>. <source>EMBO J.</source>
<volume>38</volume>:<fpage>e100730</fpage>. doi: <pub-id pub-id-type="doi">10.15252/embj.2018100730</pub-id>, PMID: <pub-id pub-id-type="pmid">30886048</pub-id>
</mixed-citation></ref><ref id="ref123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanaveski</surname><given-names>T.</given-names></name><name><surname>Molchanova</surname><given-names>S.</given-names></name><name><surname>Pham</surname><given-names>D. D.</given-names></name><name><surname>Schafer</surname><given-names>A.</given-names></name><name><surname>Pajanoja</surname><given-names>C.</given-names></name><name><surname>Narvik</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>PGC-1alpha Signaling increases GABA(A) receptor subunit alpha2 expression, GABAergic neurotransmission and anxiety-like behavior in mice</article-title>. <source>Front. Molec. Neurosci.</source>
<volume>14</volume>:<fpage>588230</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2021.588230</pub-id>, PMID: <pub-id pub-id-type="pmid">33597848</pub-id>
</mixed-citation></ref><ref id="ref124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varghese</surname><given-names>M.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Trageser</surname><given-names>K. J.</given-names></name><name><surname>Pasinetti</surname><given-names>G. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Peroxisome proliferator activator receptor gamma coactivator-1alpha overexpression in amyotrophic lateral sclerosis: A tale of two Transgenics</article-title>. <source>Biomol. Ther.</source>
<volume>10</volume>:<fpage>760</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biom10050760</pub-id>, PMID: <pub-id pub-id-type="pmid">32414179</pub-id>
</mixed-citation></ref><ref id="ref125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villena</surname><given-names>J. A.</given-names></name></person-group> (<year>2015</year>). <article-title>New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond</article-title>. <source>FEBS J.</source>
<volume>282</volume>, <fpage>647</fpage>&#x02013;<lpage>672</lpage>. doi: <pub-id pub-id-type="doi">10.1111/febs.13175</pub-id>, PMID: <pub-id pub-id-type="pmid">25495651</pub-id>
</mixed-citation></ref><ref id="ref126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldman</surname><given-names>M.</given-names></name><name><surname>Bellner</surname><given-names>L.</given-names></name><name><surname>Vanella</surname><given-names>L.</given-names></name><name><surname>Schragenheim</surname><given-names>J.</given-names></name><name><surname>Sodhi</surname><given-names>K.</given-names></name><name><surname>Singh</surname><given-names>S. P.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Epoxyeicosatrienoic acids regulate adipocyte differentiation of mouse 3T3 cells, via PGC-1alpha activation, which is required for HO-1 expression and increased&#x0202f;mitochondrial function</article-title>. <source>Stem Cells Dev.</source>
<volume>25</volume>, <fpage>1084</fpage>&#x02013;<lpage>1094</lpage>. doi: <pub-id pub-id-type="doi">10.1089/scd.2016.0072</pub-id><pub-id pub-id-type="pmid">27224420</pub-id>
</mixed-citation></ref><ref id="ref127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Hao</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Mitigation of honokiol on fluoride-induced mitochondrial oxidative stress, mitochondrial dysfunction, and cognitive deficits through activating AMPK/PGC-1alpha/Sirt3</article-title>. <source>J. Hazard. Mater.</source>
<volume>437</volume>:<fpage>129381</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhazmat.2022.129381</pub-id>, PMID: <pub-id pub-id-type="pmid">35752048</pub-id>
</mixed-citation></ref><ref id="ref128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Guan</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>C. L.</given-names></name><name><surname>Ruan</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Kai</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Medioresinol as a novel PGC-1alpha activator prevents pyroptosis of endothelial cells in ischemic stroke through PPARalpha-GOT1 axis</article-title>. <source>Pharmacol. Res.</source>
<volume>169</volume>:<fpage>105640</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.phrs.2021.105640</pub-id>, PMID: <pub-id pub-id-type="pmid">33915296</pub-id>
</mixed-citation></ref><ref id="ref129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>J. J.</given-names></name><name><surname>Diao</surname><given-names>S.</given-names></name><name><surname>Kwak</surname><given-names>Y. D.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Zhi</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Metabolic stress modulates Alzheimer's beta-secretase gene transcription via SIRT1-PPARgamma-PGC-1 in neurons</article-title>. <source>Cell Metab.</source>
<volume>17</volume>, <fpage>685</fpage>&#x02013;<lpage>694</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2013.03.016</pub-id>, PMID: <pub-id pub-id-type="pmid">23663737</pub-id>
</mixed-citation></ref><ref id="ref130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Ding</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>The effects of NAD+ on apoptotic neuronal death and mitochondrial biogenesis and function after glutamate excitotoxicity</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>15</volume>, <fpage>20449</fpage>&#x02013;<lpage>20468</lpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms151120449</pub-id>, PMID: <pub-id pub-id-type="pmid">25387075</pub-id>
</mixed-citation></ref><ref id="ref131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Ruan</surname><given-names>W.</given-names></name><name><surname>Mi</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Cao</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Balasubramide derivative 3C modulates microglia activation via CaMKKbeta-dependent AMPK/PGC-1alpha pathway in neuroinflammatory conditions</article-title>. <source>Brain Behav. Immun.</source>
<volume>67</volume>, <fpage>101</fpage>&#x02013;<lpage>117</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbi.2017.08.006</pub-id>, PMID: <pub-id pub-id-type="pmid">28803158</pub-id>
</mixed-citation></ref><ref id="ref132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>H. R.</given-names></name><name><surname>Guo</surname><given-names>M. N.</given-names></name><name><surname>Ma</surname><given-names>S. F.</given-names></name><name><surname>Yun</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>W. N.</given-names></name></person-group> (<year>2020</year>). <article-title>Adult conditional knockout of PGC-1alpha in GABAergic neurons causes exaggerated startle reactivity, impaired short-term habituation and hyperactivity</article-title>. <source>Brain Res. Bull.</source>
<volume>157</volume>, <fpage>128</fpage>&#x02013;<lpage>139</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.brainresbull.2020.02.005</pub-id>, PMID: <pub-id pub-id-type="pmid">32057952</pub-id>
</mixed-citation></ref><ref id="ref133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title><italic>Lactobacillus plantarum</italic> DP189 reduces alpha-SYN aggravation in MPTP-induced Parkinson's disease mice via regulating oxidative damage, inflammation, and gut microbiota disorder</article-title>. <source>J. Agric. Food Chem.</source>
<volume>70</volume>, <fpage>1163</fpage>&#x02013;<lpage>1173</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.jafc.1c07711</pub-id>, PMID: <pub-id pub-id-type="pmid">35067061</pub-id>
</mixed-citation></ref><ref id="ref134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>H.</given-names></name><name><surname>Zhan</surname><given-names>L. P.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Y. P.</given-names></name><name><surname>Pei</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name></person-group> (<year>2019</year>). <article-title>Dl-3n-butylphthalide reduces oxygen-glucose deprivation-induced endothelial cell&#x0202f;damage by increasing PGC-1alpha</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source>
<volume>23</volume>, <fpage>4481</fpage>&#x02013;<lpage>4490</lpage>. doi: <pub-id pub-id-type="doi">10.26355/eurrev20190517960</pub-id><pub-id pub-id-type="pmid">31173325</pub-id>
</mixed-citation></ref><ref id="ref135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Zheng</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Tetramethylpyrazine nitrone improves motor dysfunction and pathological manifestations by activating the PGC-1alpha/Nrf2/HO-1 pathway in ALS mice</article-title>. <source>Neuropharmacology</source>
<volume>182</volume>:<fpage>108380</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuropharm.2020.108380</pub-id>, PMID: <pub-id pub-id-type="pmid">33152451</pub-id>
</mixed-citation></ref><ref id="ref136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weydt</surname><given-names>P.</given-names></name><name><surname>Pineda</surname><given-names>V. V.</given-names></name><name><surname>Torrence</surname><given-names>A. E.</given-names></name><name><surname>Libby</surname><given-names>R. T.</given-names></name><name><surname>Satterfield</surname><given-names>T. F.</given-names></name><name><surname>Lazarowski</surname><given-names>E. R.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration</article-title>. <source>Cell Metab.</source>
<volume>4</volume>, <fpage>349</fpage>&#x02013;<lpage>362</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2006.10.004</pub-id>, PMID: <pub-id pub-id-type="pmid">17055784</pub-id>
</mixed-citation></ref><ref id="ref137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weydt</surname><given-names>P.</given-names></name><name><surname>Soyal</surname><given-names>S. M.</given-names></name><name><surname>Gellera</surname><given-names>C.</given-names></name><name><surname>Didonato</surname><given-names>S.</given-names></name><name><surname>Weidinger</surname><given-names>C.</given-names></name><name><surname>Oberkofler</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>The gene coding for PGC-1alpha modifies age at onset in Huntington's disease</article-title>. <source>Mol. Neurodegener.</source>
<volume>4</volume>:<fpage>3</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1750-1326-4-3</pub-id>, PMID: <pub-id pub-id-type="pmid">19133136</pub-id>
</mixed-citation></ref><ref id="ref138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>W.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Acrolein aggravates secondary brain injury after intracerebral Hemorrhage through Drp1-mediated mitochondrial oxidative damage in mice</article-title>. <source>Neurosci. Bull.</source>
<volume>36</volume>, <fpage>1158</fpage>&#x02013;<lpage>1170</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12264-020-00505-7</pub-id>, PMID: <pub-id pub-id-type="pmid">32436179</pub-id>
</mixed-citation></ref><ref id="ref139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Dong</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Guan</surname><given-names>T.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Liraglutide regulates mitochondrial quality control system through PGC-1alpha in a&#x0202f;mouse model of Parkinson's disease</article-title>. <source>Neurotox. Res.</source>
<volume>40</volume>, <fpage>286</fpage>&#x02013;<lpage>297</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12640-021-00460-9</pub-id><pub-id pub-id-type="pmid">35043376</pub-id>
</mixed-citation></ref><ref id="ref140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Deng</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Targeting Gas6/TAM in cancer cells and tumor microenvironment</article-title>. <source>Mol. Cancer</source>
<volume>17</volume>:<fpage>20</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-018-0769-1</pub-id>, PMID: <pub-id pub-id-type="pmid">29386018</pub-id>
</mixed-citation></ref><ref id="ref141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Z.</given-names></name><name><surname>Valenza</surname><given-names>M.</given-names></name><name><surname>Cui</surname><given-names>L.</given-names></name><name><surname>Leoni</surname><given-names>V.</given-names></name><name><surname>Jeong</surname><given-names>H. K.</given-names></name><name><surname>Brilli</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Peroxisome-proliferator-activated receptor gamma coactivator 1 alpha contributes to dysmyelination in experimental models of Huntington's disease</article-title>. <source>J. Neurosci.</source>
<volume>31</volume>, <fpage>9544</fpage>&#x02013;<lpage>9553</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1291-11.2011</pub-id>, PMID: <pub-id pub-id-type="pmid">21715619</pub-id>
</mixed-citation></ref><ref id="ref142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xin</surname><given-names>Z.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>FOXO1/3: potential suppressors of fibrosis</article-title>. <source>Ageing Res. Rev.</source>
<volume>41</volume>, <fpage>42</fpage>&#x02013;<lpage>52</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.arr.2017.11.002</pub-id>, PMID: <pub-id pub-id-type="pmid">29138094</pub-id>
</mixed-citation></ref><ref id="ref143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Lenahan</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Sodium benzoate attenuates secondary brain injury by inhibiting neuronal apoptosis and reducing mitochondria-mediated oxidative stress in a rat model of intracerebral Hemorrhage: possible involvement of DJ-1/Akt/IKK/NFkappaB pathway</article-title>. <source>Front. Molec. Neurosci.</source>
<volume>12</volume>:<fpage>105</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2019.00105</pub-id>, PMID: <pub-id pub-id-type="pmid">31114478</pub-id>
</mixed-citation></ref><ref id="ref144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>W.</given-names></name><name><surname>Signore</surname><given-names>A. P.</given-names></name><name><surname>Iwai</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>G.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Rapidly increased neuronal mitochondrial biogenesis after hypoxic-ischemic brain injury</article-title>. <source>Stroke</source>
<volume>39</volume>, <fpage>3057</fpage>&#x02013;<lpage>3063</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.108.520114</pub-id>, PMID: <pub-id pub-id-type="pmid">18723421</pub-id>
</mixed-citation></ref><ref id="ref145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshimura</surname><given-names>S.</given-names></name><name><surname>Sakai</surname><given-names>N.</given-names></name><name><surname>Uchida</surname><given-names>K.</given-names></name><name><surname>Yamagami</surname><given-names>H.</given-names></name><name><surname>Ezura</surname><given-names>M.</given-names></name><name><surname>Okada</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Endovascular therapy in ischemic stroke with acute large-vessel occlusion: recovery by endovascular salvage for cerebral ultra-acute embolism Japan registry 2</article-title>. <source>J. Am. Heart Assoc.</source>
<volume>7</volume>:<fpage>8796</fpage>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.118.008796</pub-id>, PMID: <pub-id pub-id-type="pmid">29695384</pub-id>
</mixed-citation></ref><ref id="ref146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>Y.</given-names></name><name><surname>Hou</surname><given-names>Y.</given-names></name><name><surname>Zhai</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Protective effects of PGC-1alpha via the mitochondrial pathway in rat brains after intracerebral hemorrhage</article-title>. <source>Brain Res.</source>
<volume>1646</volume>, <fpage>34</fpage>&#x02013;<lpage>43</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.brainres.2016.04.076</pub-id>, PMID: <pub-id pub-id-type="pmid">27178364</pub-id>
</mixed-citation></ref><ref id="ref147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>AdipoRon protects against secondary brain injury after intracerebral Hemorrhage via alleviating mitochondrial dysfunction: possible involvement of AdipoR1-AMPK-PGC1alpha pathway</article-title>. <source>Neurochem. Res.</source>
<volume>44</volume>, <fpage>1678</fpage>&#x02013;<lpage>1689</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11064-019-02794-5</pub-id>, PMID: <pub-id pub-id-type="pmid">30982205</pub-id>
</mixed-citation></ref><ref id="ref148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehnder</surname><given-names>T.</given-names></name><name><surname>Petrelli</surname><given-names>F.</given-names></name><name><surname>Romanos</surname><given-names>J.</given-names></name><name><surname>De Oliveira</surname><given-names>F. E.</given-names></name><name><surname>Lewis</surname><given-names>T. J.</given-names></name><name><surname>Deglon</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Mitochondrial biogenesis in developing astrocytes regulates astrocyte maturation and synapse formation</article-title>. <source>Cell Rep.</source>
<volume>35</volume>:<fpage>108952</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2021.108952</pub-id>, PMID: <pub-id pub-id-type="pmid">33852851</pub-id>
</mixed-citation></ref><ref id="ref149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Alpha-Lipoic acid attenuates MPTP/MPP(+)-induced neurotoxicity: roles of&#x0202f;SIRT1-dependent PGC-1alpha Signaling pathways</article-title>. <source>Neurotox. Res.</source>
<volume>40</volume>, <fpage>410</fpage>&#x02013;<lpage>419</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12640-022-00479-6</pub-id><pub-id pub-id-type="pmid">35146598</pub-id>
</mixed-citation></ref><ref id="ref150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Qian</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Gasdermin D serves as a key executioner of pyroptosis in experimental cerebral ischemia and reperfusion model both in vivo and in vitro</article-title>. <source>J. Neurosci. Res.</source>
<volume>97</volume>, <fpage>645</fpage>&#x02013;<lpage>660</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jnr.24385</pub-id>, PMID: <pub-id pub-id-type="pmid">30600840</pub-id>
</mixed-citation></ref><ref id="ref151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y. J.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name></person-group> (<year>2021</year>). <article-title>Sulforaphane protects intestinal epithelial cells against lipopolysaccharide-induced injury by activating the AMPK/SIRT1/PGC-1a pathway</article-title>. <source>Bioengineered</source>
<volume>12</volume>, <fpage>4349</fpage>&#x02013;<lpage>4360</lpage>. doi: <pub-id pub-id-type="doi">10.1080/21655979.2021.1952368</pub-id>, PMID: <pub-id pub-id-type="pmid">34308769</pub-id>
</mixed-citation></ref><ref id="ref152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Gu</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>GPR39 agonist TC-G 1008 promoted mitochondrial biogenesis and improved Antioxidative capability via CREB/PGC-1alpha pathway following intracerebral Hemorrhage in mice</article-title>. <source>Transl. Stroke Res.</source> doi: <pub-id pub-id-type="doi">10.1007/s12975-024-01240-1</pub-id></mixed-citation></ref><ref id="ref153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Z. J.</given-names></name><name><surname>Zhu</surname><given-names>L. Z.</given-names></name><name><surname>Qiu</surname><given-names>H.</given-names></name><name><surname>Zheng</surname><given-names>W. Y.</given-names></name><name><surname>You</surname><given-names>P. T.</given-names></name><name><surname>Chen</surname><given-names>S. H.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Neferine inhibits BMECs pyroptosis and maintains blood-brain barrier integrity in ischemic stroke by triggering a cascade reaction of PGC-1alpha</article-title>. <source>Sci. Rep.</source>
<volume>14</volume>:<fpage>14438</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-024-64815-w</pub-id>, PMID: <pub-id pub-id-type="pmid">38910141</pub-id>
</mixed-citation></ref><ref id="ref154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>J.</given-names></name><name><surname>Dong</surname><given-names>W.</given-names></name><name><surname>Qin</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Xiao</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Roflupram exerts neuroprotection via activation of CREB/PGC-1alpha signalling in&#x0202f;experimental models of Parkinson's disease</article-title>. <source>Br. J. Pharmacol.</source>
<volume>177</volume>, <fpage>2333</fpage>&#x02013;<lpage>2350</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bph.14983</pub-id><pub-id pub-id-type="pmid">31972868</pub-id>
</mixed-citation></ref><ref id="ref155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Shao</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Cui</surname><given-names>G.</given-names></name><name><surname>Gao</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Tetramethylpyrazine analogue T-006 exerts neuroprotective effects against&#x0202f;6-Hydroxydopamine-induced Parkinson's disease in vitro and in vivo</article-title>. <source>Oxidative Med. Cell. Longev.</source>
<volume>2019</volume>:<fpage>8169125</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2019/8169125</pub-id></mixed-citation></ref><ref id="ref156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>SIRT1/PGC-1alpha Signaling promotes mitochondrial functional recovery and reduces apoptosis after intracerebral Hemorrhage in rats</article-title>. <source>Front. Molec. Neurosci.</source>
<volume>10</volume>:<fpage>443</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2017.00443</pub-id>, PMID: <pub-id pub-id-type="pmid">29375306</pub-id>
</mixed-citation></ref><ref id="ref157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H. R.</given-names></name><name><surname>Wang</surname><given-names>Z. Y.</given-names></name><name><surname>Zhu</surname><given-names>X. L.</given-names></name><name><surname>Wu</surname><given-names>X. X.</given-names></name><name><surname>Li</surname><given-names>E. G.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name></person-group> (<year>2010</year>). <article-title>Icariin protects against brain injury by enhancing SIRT1-dependent PGC-1alpha&#x0202f;expression in experimental stroke</article-title>. <source>Neuropharmacology</source>
<volume>59</volume>, <fpage>70</fpage>&#x02013;<lpage>76</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuropharm.2010.03.017</pub-id><pub-id pub-id-type="pmid">20381504</pub-id>
</mixed-citation></ref></ref-list></back></article>